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ABSTRACT

IMPACT OF N-ACETYL-L-CYSTEINE ON THE PATHOLOGY OF EXPERIMENTAL
PARKINSON’S DISEASE IN VIVO

By
Negin Nouraei
December 2015

Dissertation supervised by Dr. Rehana K. Leak and Dr. David Johnson
Parkinson’s disease is a progressive neurodegenerative disorder associated with
disruptions in motor as well as non-motor functions, such as cognitive and olfactory
impairments. Postmortem tissue from Parkinson’s patients shows evidence of oxidative stress in
dopaminergic neurons and hallmark proteinaceous inclusions known as Lewy bodies in multiple
brain regions spanning the medulla oblongata to the telencephalon. There are no therapies that
decelerate the progression of this disease. Thus, the major goal of the present study was to test
the therapeutic potential of two neuroprotective molecules, the antioxidant thiol N-acetyl-Lcysteine (NAC) and the steroid neuromodulator dehyroepiandrosterone sulfate (DHEAS), in
experimental models of Parkinson’s disease in vivo. To accomplish this goal, we first established
multiple animal models of Parkinson’s disease that mimicked oxidative and/or proteotoxic stress:
the 6-hydroxydopamine (6-OHDA) model of dopaminergic neurodegeneration and the alpha-
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synuclein model of Lewy-like pathology. NAC offered only transient protection in the 6-OHDA
model, as demonstrated by multiple histological techniques that were validated in the present
study. Indeed, NAC was mildly toxic at doses previously employed in the clinic, with
implications for the long-term use of NAC in patients with chronic neurodegenerative
conditions. We also developed a model of Lewy-like pathology in the hippocampus in which to
examine the effects of DHEAS upon memory function. Although DHEAS failed to affect
memory, we subsequently discovered that infusions of waterbath-sonicated alpha-synuclein
fibrils into hippocampal CA2/CA3 led to robust Lewy-like pathology in some (but not all) of the
brain regions that send first-order efferent projections to the hippocampus—the amygdala,
entorhinal cortex, and contralateral CA3. Similar to the human condition, we collected evidence
of selective vulnerability to alpha-synucleinopathy, as the septohippocampal projections were
spared in our model. Notably, Lewy-like pathology in the hippocampus was statistically
correlated with memory and olfactory deficits. Taken together, these studies reveal a novel
model of proteinopathy in the hippocampus, which is known to develop Lewy pathology at midto-end stages of Parkinson’s disease and may be partly responsible for cognitive deficits in this
condition. This model can now be used to test neuroprotective drug candidates that have the
potential to ameliorate proteinopathic stress and improve neurological outcomes.
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Introduction

The impact of Parkinson’s disease

Parkinson’s disease is the second most common neurodegenerative disorder. It affects 1–3% of
the global population over 50 years of age—about 1 million people in the United States and more
than 5 million people worldwide (Dehay et al., 2015). A systematic review of Parkinson’s
incidence studies have shown that that aging plays a major role in the development of
Parkinson's disease (Pringsheim et al., 2014). Parkinson’s disease affects 1.5-fold more men than
women (Wooten et al., 2004).

Parkinson’s disease is characterized by motor deficits such as bradykinesia, rigidity, postural
instability and resting tremor, which are generally attributed to the loss of dopaminergic neurons
in the substantia nigra, pars compacta, and a subsequent decrease in dopamine levels in the
striatum, the site of termination of the nigrostriatal pathway (Alexander, 2004). Parkinson’s
patients are also known to suffer from non-motor symptoms, such as psychosis, memory loss,
and dementia, which do not respond well to conventional dopaminergic therapies and severely
reduce quality of life.

Parkinson’s disease imposes a significant economic burden on patients and the healthcare
system. The economic burden of Parkinson's disease is estimated at a minimum of $14.4 billion
per year in the United States, at a cost of approximately $22,800 per patient (Kowal et al., 2013).
Nursing home care is a major contributor to the medical costs, rather than medical treatment
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itself. The prevalence and economic burden of Parkinson’s disease are projected to grow
substantially over the next few decades with the projected explosion of the aging population
(Kowal et al., 2013).

The hallmarks of Parkinson’s disease are progressive neuronal degeneration and the presence of
neuronal alpha-synuclein-bearing inclusions known as Lewy bodies and Lewy neurites (Dehay et
al., 2015). Currently there is no effective neuroprotective or neurorestorative therapy to cure or
slow down the progression of this disease, at least partly because the pathophysiological
mechanisms underlying the disease are incompletely understood.

Patterns of neurodegeneration — Parkinson’s disease staging

Heiko Braak and coworkers have proposed neuropathological staging criteria for postmortem
tissue from Parkinson’s victims (Braak et al., 2003a). These criteria are based upon the
topographical extent of the alpha-synuclein inclusions. As mentioned above, Lewy bodies and
Lewy neurites are predominantly composed of the misfolded alpha-synuclein protein (Baba et
al., 1998, Duda et al., 2000). Lewy neurites are found in neuronal processes and globular Lewy
bodies are housed within neuronal perikarya (Pollanen et al., 1993, Dickson, 2012).

Based on the presence of Lewy bodies and Lewy neurites, there are six Braak stages along a
continuum (Braak et al., 2003a). The presymptomatic phase of Parkinson’s disease consists of
stages I, II, and III and the symptomatic phases consist of stages IV, V and VI. In stage I lesions
are found in the dorsal IX/X motor nucleus and/or intermediate reticular formation (Braak et al.,
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2003a). The anterior olfactory nucleus is also frequently affected with alpha-synucleinopathy in
stage I, which probably underlies the loss of smell that almost all Parkinson’s patients suffer
from years before the onset of motor deficits. Gastrointestinal symptoms are also present in these
pre-symptomatic phases and are strongly associated with Lewy pathology in the enteric nervous
system (Palma and Kaufmann, 2014). The pathology in the anterior olfactory nucleus spreads
more slowly into interconnected brain regions compared to that expanding from the brainstem.
Stage II (medulla, pontine tegmentum) involves denser pathology in those areas first involved in
stage I and additional new pathology in the caudal raphe nuclei, the gigantocellular reticular
nucleus, and the coeruleus–subcoeruleus complex. Stage III (midbrain) consists of dopaminergic
lesions in the pars compacta of the substantia nigra. Stage IV (basal prosencephalon and
mesocortex) consists of pathology of earlier stages plus additional lesions in the prosencephalon.
Cortical involvement begins at this late stage but is still confined to the temporal mesocortex
(transentorhinal region) and allocortex (CA2 plexus). Stage V (neocortex) consists of pathology
in all of the previously involved subcortical and mesocortical structures, plus additional
pathology in higher order sensory association areas of the neocortex and prefrontal cortex. Stage
VI (neocortex) affects the entire neocortex, including first-order sensory association areas of
neocortex and premotor areas, with occasional mild changes in primary sensory areas and the
primary motor fields.
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Fig. 1. Caudo-rostral progression of Lewy bodies in the brain in Parkinson’s disease. Reprinted from “Milestones
in Parkinson's disease—Clinical and pathologic features,” by G. Halliday, A. Lees, and M. Stern, 2011, Movement
Disorders, 26, p. 1015-1021. Copyright 2011, by John Wiley and Sons. Reprinted with permission.

Patterns of neurodegeneration — Alzheimer’s disease staging

Similar to Parkinson’s disease, Alzheimer’s disease is associated with the spread of aggregated
proteins across multiple brain regions. The major hallmarks of Alzheimer’s disease are the
appearance of neurofibrillary tangles and neuropil threads and senile plaques containing betaamyloid (Ittner et al., 2010). Postmortem studies of Alzheimer’s patients have mostly focused
upon neurodegeneration in the cerebral cortex. The cerebral cortex is responsible for higherorder executive function, learning, and memory. In Alzheimer’s disease, the temporal
mesocortex and allocortex are affected with tau pathology before neocortex (Braak et al., 2006).
Based on the spread of tau inclusions, Braak reported six stages in Alzheimer’s disease.
Alzheimer’s disease stages I and II involve the transentorhinal region. Subsequently, the tau
pathology extends into entorhinal regions, followed by involvement of the first and second CA
fields of the hippocampal formation. In Alzheimer’s disease stages III-IV (limbic system) there
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is exacerbation of pathology in all previously involved regions, and initiation of pathology in
neocortical higher order association areas. In end stages V-VI (neocortex), neocortical lesions
become more severe and extend into primary sensorimotor areas of the frontal and parietal
neocortex (Braak et al., 2006). Initial Alzheimer’s disease pathology in limbic regions is
associated with mild cognitive impairments in early stages of the disease (Weintraub et al.,
2012). As neurodegeneration spreads to neocortical regions, more severe symptoms emerge and
the full dementia syndrome becomes manifest (Braak and Braak, 1996). In Alzheimer’s disease,
both memory and executive function are strongly correlated with neuronal cell death in the
entorhinal cortex (Albert, 1996, Gomez-Isla et al., 1996, Gomez-Isla et al., 1997).

In Alzheimer’s disease, beta-amyloid formation begins in the neocortex. However, the total
numbers of amyloid plaques do not correlate with the severity of the disease or with neuronal
cell death (DaRocha-Souto et al., 2011). Furthermore, atrophy in the cerebral cortex follows the
progression of tau pathology and not of amyloid formations (Arriagada et al., 1992, Josephs et
al., 2008, Whitwell et al., 2008).

Cognitive impairments in Parkinson's disease dementia and dementia with Lewy bodies

The mechanisms underlying the cognitive deficits in Parkinson’s disease and dementia with
Lewy bodies are heterogeneous. Parkinson’s disease dementia and dementia with Lewy bodies
are both characterized by neuronal cell death and the formation of limbic and cortical Lewy
pathology (Aarsland, 2016, Bellucci et al., 2016). Alzheimer’s disease-related changes such as
amyloid plaques and tau inclusions also contribute to the pathogenesis of both Parkinson’s
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disease dementia and dementia with Lewy bodies. However, the latter two pathologies are more
common in dementia with Lewy bodies than in Parkinson’s disease dementia. In Parkinson’s
disease dementia, parkinsonism typically occurs prior to the onset of cognitive impairments. In
contrast, in dementia with Lewy bodies, cognitive deficits emerge after the onset of motor
symptoms, or emerge almost simultaneously (Aarsland, 2016). The hippocampus develops Lewy
pathology in Braak stages III and IV in Parkinson’s disease. As mentioned above, stages V and
VI are associated with the formation of alpha-synuclein inclusions in the expansive neocortex
(Braak et al., 2003a). Alpha-synucleinopathy in the hippocampus and neocortex are strongly
correlated with cognitive deficits in Parkinson’s disease (Kalaitzakis and Pearce, 2009). To date,
there are few models of Parkinson’s disease dementia and of Lewy pathology in the
hippocampus. Therefore, it has been difficult to establish whether Lewy pathology elicits or is
merely correlated with impairments of cognitive function.

Pharmacological treatments for dementia in both Parkinson’s disease dementia and dementia
with Lewy bodies are largely limited to cholinesterase inhibitors and memantine, a partial
NMDA-antagonist (Aisen et al., 2012). However, there is insufficient evidence to support the
efficacy of available treatments. Thus, there is an urgent unmet need for agents to help control
dementia and/or to decelerate the cognitive decline in Parkinson’s disease dementia and
dementia with Lewy bodies.
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The transmission of Lewy pathology in Parkinson’s disease

Alpha-synuclein is a 14kDa protein composed of 140 amino acids and is found in the nucleus,
presynaptic terminals, cytosol, mitochondrial membrane, and endoplasmic reticulum (Maroteaux
et al., 1988, Guardia-Laguarta et al., 2014). As mentioned above, alpha-synuclein is one of the
main components of Lewy bodies and Lewy neurites. Although it has been studied for many
years, the exact function of alpha-synuclein remains unknown. Some studies suggest that alphasynuclein directly interacts with membrane phospholipids and plays a dynamic role in vesicle
trafficking during neurotransmitter release (Recasens and Dehay, 2014). Mutations in six genes
encoding for alpha-synuclein (p.A53T, p.A30P, p.E64K, p.H50Q, p.G51D, p.A53E) have been
found to cause autosomal-dominant forms of Parkinson’s disease (Polymeropoulos et al., 1997,
Kruger et al., 1998, Athanassiadou et al., 1999, Spira et al., 2001, Zarranz et al., 2004, Ki et al.,
2007, Choi et al., 2008, Puschmann et al., 2009, Appel-Cresswell et al., 2013, Lesage et al.,
2013).

Alpha-synuclein is a natively unfolded protein with no defined structure in aqueous solutions
(Stefanis, 2012). Under pathological conditions such as oxidative stress or following posttranslational modifications, alpha-synuclein can adopt an oligomeric or fibrillar conformation,
leading to the formation of Lewy bodies (Recasens and Dehay, 2014). The corresponding
misfolded species expose beta sheet stretches that are prone to protein-protein interactions and
subsequent formation of detergent-insoluble aggregations (Saxena and Caroni, 2011).
Approximately 90% of alpha-synuclein found in Lewy bodies is phosphorylated at serine 129
(Sato et al., 2013). In contrast, only 4% or less of total alpha-synuclein is phosphorylated at this
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residue under physiological conditions. However, it remains unclear whether the conformational
changes and accumulation of alpha-synuclein promote disease through a toxic gain or loss of
function.

Recent evidence suggests that misfolded alpha-synuclein can be transmitted from cell to cell
across neuroanatomically linked brain regions (Luk et al., 2012a, Luk et al., 2012b, Jucker and
Walker, 2013). The concept of cell-to-cell transmissibility is consistent with Braak staging, as
the staging theory also describes the progressive involvement of additional brain regions with the
passage of time (Braak et al., 2003a). In addition, Braak has observed that the areas sequentially
corralled into exhibiting Lewy pathology are connected by neuroanatomical circuitry (Braak et
al., 2003b).

Recent studies suggest that cell-to-cell transmission of alpha-synuclein is mediated by the release
of fibrillar or oligomeric alpha-synuclein by exocytosis or necrosis into the extracellular milieu
and subsequent uptake into neighboring neurons through endocytotic pathways (Luk et al., 2009,
Volpicelli-Daley et al., 2011). Once inside the neighboring cell, misfolded

lpha-synuclein

might continue to act as a seed or template, promoting the misfolding and aggregation of
additional alpha-synuclein molecules, eventually resulting in further inclusion formation and
Lewy pathology (Luk et al., 2009, Volpicelli-Daley et al., 2011).

Recent studies strongly suggest that alpha-synucleinopathy can be transmitted from the diseased
host brain to healthy, young transplanted tissue. For example, Lewy bodies have been detected in
fetal mesencephalic neurons that were transplanted into the striatum of Parkinson’s patients 12-
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16 years prior to death and postmortem analyses (Angot et al., 2010). Host-to-graft transfer of
alpha-synuclein has also been confirmed in animal studies, as post-mitotic dopaminergic neurons
grafted into the striatum of mice overexpressing human alpha-synuclein exhibit human alphasynuclein immunoreactivity six months after transplantation (Hansen et al., 2011). The latter
study further suggests that multiple forms of alpha-synuclein, including monomers, oligomers
and fibrils, can be taken up by neurons (Hansen et al., 2011). Intracerebral injections of brain
homogenates derived from old symptomatic alpha-synuclein transgenic mice into the neocortex
and striatum of young asymptomatic transgenic mice accelerate the spread of alphasynucleinopathy throughout the central nervous system (olfactory bulb to the spinal cord), and
reduce lifespan (Luk et al., 2012a). Furthermore, injections of synthetic recombinant alphasynuclein fibrils alone are sufficient to initiate and propagate alpha-synuclein pathology within
interconnected brain regions in healthy wildtype mice in a time-dependent manner (Luk et al.,
2012b). Exogenous alpha-synuclein fibrils induce the misfolding and aggregation of endogenous
alpha-synuclein molecules and lead to cell loss in the substantia nigra and impairments in motor
coordination. Finally, recent in vitro studies have demonstrated that alpha-synuclein fibrils can
recruit endogenous alpha-synuclein to form pathologic, insoluble aggregates in cultured cells
overexpressing alpha-synuclein (Luk et al., 2009, Hansen et al., 2011, Volpicelli-Daley et al.,
2011). It is important to note that the development of Lewy-like pathology in these models is
abolished in cells from alpha-synuclein knockout mice, strongly supporting the view that it is the
misfolding of endogenous alpha-synuclein molecules that is responsible for the emergence of
inclusion bodies (Bernis et al., 2015). In addition to the spread of the pathology through
interconnected neural networks, selective regional vulnerabilities may also play a role in the
determining the topography of Lewy body formations.
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Fig. 2. Hypothetical model of alpha-synuclein toxicity and spread of pathology in Parkinson’s disease and
Parkinson’s disease dementia. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews
Neuroscience (“Parkinson's disease dementia: convergence of [alpha]-synuclein, tau and amyloid-[beta]
pathologies,” by David J. Irwin, Virginia M.-Y. Lee, John Q Trojanowski, 2013, Nature Reviews Neuroscience, 14,
p. 626–636). Copyright (2013).

Neurodegenerative Mechanisms in Parkinson’s disease —Accumulation of misfolded proteins

Similar to other neurodegenerative disorders, Parkinson’s disease is characterized by the
accumulation of protein aggregates and disruptions in the ubiquitin proteasome system and the
autophagy-lysosomal pathway. Soluble alpha-synuclein is degraded by the proteasome. Mutant
alpha-synuclein adopts a fibrillar structure that can directly interact with the 20S core of the
proteasome and decrease its proteolytic activity (Lindersson et al., 2004). Loss of proteasome
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function and 20S proteasomal subunits has been reported in the substantia nigra of Parkinson’s
patients (McNaught and Jenner, 2001, Fishman-Jacob et al., 2009).

Molecular chaperones such as the heat shock proteins Hsp70/Hsc70, Hsp40, and Hsp90 are
critical for maintaining protein homeostasis (Ebrahimi-Fakhari et al., 2011b). Sequestration of
chaperones in Lewy bodies might result in a general depletion of chaperones in experimental
models of Parkinson’s disease as well as in patients. Ubiquitin proteasomal dysfunction has been
shown to elicit alpha-synuclein aggregation in primary mesencenphalic neurons, dopaminergic
neuronal cell lines, as well as in animal models (McNaught et al., 2002a, McNaught et al.,
2002b, Sun et al., 2006). Autosomal recessive loss-of-function mutations in the E3 ubiquitin
ligase parkin are associated with familial Parkinson’s disease (Imai et al., 2000, Shimura et al.,
2000). Furthermore, mutations in ubiquitin carboxy-terminal hydrolase L1 are also associated
with familial Parkinson’s disease and lead to impairments in protein quality control (Leroy et al.,
1998). The accumulation of ubiquitinated proteins, heat shock proteins, and components of the
ubiquitin proteasome system within Lewy bodies and the inhibition of proteasome activity in the
substantia nigra all suggest that loss of proteasome function plays an important role in the
pathogenesis of Parkinson’s disease (Lennox et al., 1989, Lowe et al., 1990, Ii et al., 1997,
Auluck et al., 2002, McNaught et al., 2002d, Schlossmacher et al., 2002) .

Impairments in the ubiquitin-proteasome system have been modeled in the substantia nigra in
order to investigate the mechanisms underlying neurodegeneration in Parkinson’s disease and to
test potential therapeutics (McNaught et al., 2002c, Petrucelli et al., 2002, Rideout et al., 2005,
Sun et al., 2006). In vitro studies suggest that proteasome inhibitors elicit relatively selective
degeneration of cultured dopamine neurons and the formation of ubiquitin and alpha-synuclein+
11

inclusions. In addition, infusions of proteasome inhibitors into animals lead to Lewy-like
inclusions in the basal ganglia (Fornai et al., 2003, McNaught et al., 2004, Xie et al., 2010). For
example, the peptide aldehyde MG132 has been shown to induce degeneration in the substantia
nigra, pars compacta, and to deplete dopamine levels in both cell culture and animal models of
Parkinson’s disease (Sun et al., 2006). Injections of the cyclic amide lactacystin into the medial
forebrain bundle of C57BL/6 mice induces dopaminergic neurodegeneration in the substantia
nigra, and this is accompanied by inhibition of proteasomal activity and the formation of alphasynuclein positive inclusions, activated glia, and decreased motor activity (Xie et al., 2010).
Thus, proteasome inhibition recapitulates many important biochemical and behavioral features of
Parkinson’s disease, making it suitable for testing potential neuroprotective therapies.

Impairments in the autophagic-lysosomal pathway can also contribute to loss of protein
homeostasis and is associated with multiple neurodegenerative diseases. For example, neuronspecific autophagy gene knockout mice have been found to develop intraneuronal aggregates and
neurodegeneration (Hara et al., 2006, Komatsu et al., 2006). Furthermore, overexpression of
alpha-synuclein has been shown to impair autophagic clearance in mammalian cells and mice by
inhibiting autophagosome formation (Winslow et al., 2010). Mutant alpha-synuclein may also
disrupt chaperone-mediated autophagy by blocking the translocation of substrates into the
lysosome through the LAMP2A lysosomal receptor (Cuervo et al., 2004, Martinez-Vicente et al.,
2008).
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Neurodegenerative mechanisms in Parkinson’s disease — Oxidative stress

The molecular mechanisms underlying the loss of dopaminergic neurons in Parkinson’s disease
still remain unclear. However, oxidative stress is thought to play an important role in
dopaminergic neurotoxicity (Blesa et al., 2015). Parkinson’s disease has long been associated
with excess production of reactive oxygen species and alterations in the metabolism of excitatory
amino acids and neurotransmitters, all of which can lead to formation of toxic byproducts.
Oxidative stress is thought to be the common underlying mechanism leading to cellular
dysfunction and cell death in both familial and sporadic forms of Parkinson’s disease (Ryan et
al., 2015). Reactive oxygen species can directly cause protein and DNA damage in addition to
lipid peroxidation. For example, oxidatively damaged proteins are present in the substantia nigra,
pars compacta in Parkinson’s disease (Yoritaka et al., 1996, Alam et al., 1997). Antioxidant
enzymes serve to blunt the impact of reactive oxygen species and include superoxide dismutase,
glutathione peroxidase, and catalase (Powers and Jackson, 2008). Deficiencies in complex I of
the mitochondrial respiratory chain, protein folding, and the ubiquitin proteasome system also
generate oxidative stress and exacerbate the toxicity of existing reactive oxygen species (Double
et al., 2010).

Neurons are post-mitotic cells with an abundance of unsaturated lipids, which makes them
particularly sensitive to peroxidation and oxidative modification (Uttara et al., 2009). In addition,
the brain has lower levels of antioxidant defenses compared to other tissues such as the liver,
which renders it especially susceptible to reactive oxygen species. Enzymes such as tyrosine
hydroxylase and monoamine oxidase make dopaminergic neurons particularly sensitive to
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oxidative stress because dopamine can be metabolized into toxic byproducts such as hydrogen
peroxide and dopamine quinones if it is not sequestered into acidic vesicles (Halliwell, 1992).
Furthermore, nigral dopaminergic neurons contain high levels of iron, which can catalyze the
Fenton reaction and generate superoxide radicals and hydrogen peroxide, thereby resulting in
further oxidative stress.

Reactive oxygen species may induce intracellular calcium influx through glutamate receptors
and elicit excitotoxicity, which may culminate in cell death (Uttara et al., 2009). Chronic
oxidative stress can also interfere with autophagic degradation system, causing incomplete
degradation of lysosomal cargo and subsequent intralysosomal accumulation of cross-linked
products such as lipofuscin, and further lysosomal dysfunction (Terman and Brunk, 2004,
Cuervo et al., 2005, Kiffin et al., 2006).

A strong link between oxidative stress and neuronal death has been established in animal models.
Paraquat, a structural analog of 1-methyl-4-phenylpyridinium (MPP+), is a redox cycling
compound and was previously widely used as an herbicide. This compound causes mitochondrial
damage by inhibition of complex I of the electron transport chain and increases the levels of
reactive oxygen species such as the superoxide free radical (Jenner, 2003, Castello et al., 2007).
Chronic administration of paraquat in mice or rats decreases the number of dopaminergic
neurons in the substantia nigra, pars compacta, and striatal levels of dopamine and impairs motor
function (McCormack et al., 2002, Shimizu et al., 2003, Thiruchelvam et al., 2003).
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Epidemiological studies suggest an association between chronic exposure to pesticides,
particularly paraquat and rotenone, and an increased risk for developing Parkinson’s disease
(Hertzman et al., 1990, Semchuk et al., 1993, Liou et al., 1996, Gorell et al., 1998). Thus,
neuroprotective therapies that target multiple pathological pathways such as mitochondrial and
ubiquitin–proteasome dysfunction are urgently needed to prevent or slow the progression of
neurodegeneration. It is likely that mitochondrial dysfunction leads to loss of protein quality
control by an increase in oxidatively damaged proteins and reduced protein clearance whereas
protein misfolding may lead to an increase in reactive oxygen species by impairing the normal
function of the mitochondrion.

Traditional and novel animal models of Parkinson’s disease

As mentioned above, there are no effective treatments to cure or slow down the progression of
Parkinson’s disease because the underlying pathophysiology is incompletely understood. In
order to accelerate the identification of a cure, it is essential to understand the mechanisms
underlying neurodegeneration in animal models and in the human condition. However, all
currently available animal models fail to mimic every aspect of the human pathology and,
perhaps as a result, the results obtained from these models have not always translated to the
clinic. Here we will discuss the strengths and limitations of several commonly used in vivo
models of Parkinson’s disease including: 1) toxicant models, such as the 6-hydroxydopamine (6OHDA) and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) models, which
selectively and rapidly destroy catecholaminergic systems through oxidative stress and
mitochondrial dysfunction; 2) agricultural chemicals such as rotenone and paraquat, which also
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lead to neurodegeneration through mitochondrial dysfunction and increased reactive oxygen
species; 3) proteasome inhibitor-induced neurodegeneration as a result of loss of protein
degradation via the ubiquitin–proteasome system (UPS) and subsequent protein aggregations; 4)
fibrillized alpha-synuclein protein and proteotoxic stress induced by protein misfolding and
aggregation. However, the specific toxicity of proteasome inhibitors would be expected to be
somewhat distinct from the toxicity of fibrillized alpha-synuclein, because many more proteins
would be affected via general loss of protein degradation through the proteasome. In contrast,
alpha-synuclein would be expected to act as a template for the seeding of neighboring alphasynuclein molecules, and may or may not encompass the misfolding of other endogenous
proteins. Below we discuss the strengths and weaknesses of each model and their contributions
to our understanding of Parkinson’s disease.

Toxicant models: 6-Hydroxydopamine

6-hydroxydopamine (6-OHDA) is an analog of dopamine with an additional hydroxyl group. It
was first described 50 years ago (Tieu, 2011, Blesa et al., 2012) and was initially reported to
induce depletion of noradrenaline in the mouse heart (Porter et al., 1963, Porter et al., 1965,
Deumens et al., 2002, Tieu, 2011). 6-OHDA has been widely used to lesion the nigrostriatal
dopaminergic pathway and thereby model Parkinson’s disease. 6-OHDA is taken up by
catecholamine transporters, including dopamine and norepinephrine transporters (Sachs and
Jonsson, 1975a, b), and can induce cell death through increased production of reactive oxygen
species such as H2O2 as well as dopamine quinones. 6-OHDA does not cross the blood-brain
barrier. Therefore, in order to induce dopaminergic neuronal loss in Parkinson’s disease models,
it needs to be directly injected into the striatum, medial forebrain bundle, or substantia nigra
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using stereotaxic brain surgery. The magnitude of the lesion depends on the dose of 6-OHDA,
the site of injection, the manufacturer of the neurotoxin, and the species of the animal used (He
et al., 2000, Smith et al., 2006, Rodriguez-Pallares et al., 2007). One major advantage of using 6OHDA in Parkinson’s disease models is the induction of motor deficits, and the ability to test
experimental therapies that reverse or lessen the histological and behavioral insult.

Toxicant models: Methyl-4-phenyl-1, 2,3,6 tetrahydropyridine (MPTP)

MPTP was accidentally discovered in 1982 when drug addicts developed acute parkinsonian
symptoms after intravenous injections of this neurotoxin. L-DOPA treatments were successful
in controlling behavioral abnormalities in these patients, suggesting similar underlying
neuropathological features as those seen in Parkinson’s patients (Sachs and Jonsson, 1975a,
Bezard et al., 1999, Tieu, 2011, Blesa et al., 2012). These findings led to the development of
rodent and nonhuman primates models of Parkinson’s disease. MPTP is highly lipophilic and can
readily pass the blood brain barrier upon systemic administration. In astrocytes, MPTP is
metabolized and converted to MPP+—the active metabolite—, which is transported into
catecholaminergic neurons through the dopamine and norepinephrine transporters. MPP+ induces
dopaminergic neurodegeneration mainly by inhibiting complex I of the electron transport chain
in mitochondria, resulting in ATP depletion, formation of reactive oxygen species, and increased
oxidative stress (Nicklas et al., 1987, Nicklas et al., 1992, Tieu, 2011, Blesa et al., 2012),
(Mizuno et al., 1987). Rats are relatively insensitive to MPTP neurotoxicity due to the lack of
monoamine oxidase-B in their brains, and currently this model is mostly employed in murine and
primate species.
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Toxin models: Lipopolysaccharide (LPS)

LPS is an endotoxin isolated from Gram-negative bacteria. It serves as a glial activator and
induces neuroinflammation as well as selective and progressive dopaminergic neuronal loss
following injections in the nigrostriatal pathway (Dutta et al., 2008, Liu and Bing, 2011). LPS
induces neuronal damage by inducing the release of the proinflammatory factors interleukin 1
and 6 (IL-1 and IL-6), tumor necrosis factors (TNF), and nitric oxide (NO), all of which activate
the immune response (Czlonkowska et al., 2002, Mosley et al., 2006, Laurie et al., 2007, Qin et
al., 2007, Liu and Bing, 2011). LPS-based models of Parkinson’s disease can be used to model
inflammation-associated dopaminergic neurodegeneration, in addition to being useful for
neuroprotective drug discovery.

Proteasome inhibitors: Lactacystin, MG132, PSI (Z-lle-Glu (OtBu)-Ala-Leu-al)

Impairment of the ubiquitin proteasome system has been reported to play an important role in
the pathogenesis of Parkinson’s disease. Systemic exposure to proteasome inhibitors causes
levodopa-responsive motor dysfunction in mice and rats (Xie et al., 2010). Naturally derived
proteasome inhibitors, as well as synthetic proteasome inhibitors (PSI), (Z-lle-Glu (OtBu)-AlaLeu-al) have been recently used to induce neurodegeneration in the substantia nigra, locus
coeruleus, dorsal motor nucleus of vagus, and the nucleus basalis of Meynert (Braak et al.,
2003a, Zarow et al., 2003, McNaught et al., 2004, McNaught and Olanow, 2006). In addition to
neuronal loss, intracytoplasmic Lewy-body-like inclusions that stained positively for alphasynuclein, ubiquitin, and other proteins have been reported in proteasome inhibitor-induced
models of Parkinson’s disease. Inhibition of proteasomal function can induce progressive
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neurodegeneration with similarities to Parkinson’s disease and may be useful in developing and
testing neuroprotective therapies (McNaught et al., 2004, McNaught and Olanow, 2006).
Unfortunately, the systemically delivered approach exhibits poor reproducibility and failed to
cause any noticeable behavioral or neuropathological abnormality in rodents in most other labs
(Bove et al., 2006). On the other hand, other labs have shown that intrastriatal infusions of
proteasome inhibitors elicit dopaminergic neurodegeneration (Fornai et al., 2004, Sun et al.,
2006).

Pesticide/Herbicide/ Fungicide models: Rotenone

Rotenone is a highly lipophilic insecticide and pesticide (Blesa et al., 2012) that can easily cross
the blood brain barrier. This neurotoxin is a strong inhibitor of mitochondrial complex I (Li et
al., 2003). Chronic exposure to rotenone has been reported to cause important features of
Parkinson’s disease, including nigrostriatal dopaminergic degeneration (Betarbet et al., 2000,
Hisahara and Shimohama, 2010) and intracellular Lewy body-like inclusions immunoreactive for
ubiquitin and alpha-synuclein (Betarbet et al., 2000, Sherer et al., 2003, Blesa et al., 2012)
Similar to Parkinson’s disease, neurodegeneration induced with rotenone expands beyond the
dopaminergic system, and is associated with toxicity in serotonin, noradrenergic, and cholinergic
neurons (Heikkila et al., 1985, Fornai et al., 2005, Hoglinger et al., 2005, Blesa et al., 2012).
Attempts to lesion animal species other than rats have not always been successful. In addition,
there are no convincing reports of human Parkinson’s disease symptoms due to rotenone
exposure (Blesa et al., 2012).
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Pesticide/Herbicide/ Fungicide models: Paraquat (N, N′-dimethyl-4,4′-bipyridinium dichloride)

Paraquat is an herbicide with structural similarities to MPP+, the active metabolite of MPTP. A
few cases of paraquat-induced Parkinson’s disease symptoms have been reported among humans
(Hoglinger et al., 2003, Hoglinger et al., 2005, Blesa et al., 2012). Paraquat exhibits its toxicity
mainly due to oxidative stress and generation of superoxide, hydroxyl, and hydrogen peroxide
radicals. Some researchers have reported that animals exhibit dose-dependent loss of striatal THpositive striatal fibers and midbrain substantia nigra neurons following systemic paraquat
exposure (Brooks et al., 1999, McCormack et al., 2005, Blesa et al., 2012). However, others
demonstrated that high doses of paraquat interfere with the function of dopamine transporters
and organic cationic transporter-3. Paraquat is therefore toxic to dopaminergic neurons in the
substantia nigra only when used in high doses (Blesa et al., 2012). Recent studies suggest that
combined exposure to paraquat and the fungicides Maneb and Ziram lead to greater risk of
developing Parkinson’s disease in humans (Zhang et al., 2010, Tanner et al., 2011, Blesa et al.,
2012). However, further investigations are needed to determine the involvement of
environmental exposures in the etiology of Parkinson’s disease.

Pathological alpha-synuclein fibril models

Lewy bodies and Lewy neurites are the neuropathological hallmark of Parkinson’s disease and
are composed of aggregated proteins such as alpha-synuclein (Spillantini et al., 1998a, Malek et
al., 2014). Virginia Lee’s lab has shown that intracellular alpha-synuclein aggregation can be
triggered by the introduction of exogenous recombinant alpha-synuclein fibrils into cultured cells
engineered to overexpress alpha-synuclein. Unlike unassembled alpha-synuclein, these alpha20

synuclein fibrils convert endogenous soluble alpha-synuclein protein into insoluble,
hyperphosphorylated, and ubiquitinated pathological forms (Luk et al., 2012a, Luk et al., 2012b).
The same authors also reported that intrastriatal inoculation of synthetic alpha-synuclein fibrils in
wild-type nontransgenic mice led to the development of motor deficits, nigral cell loss, and
Parkinson’s-like Lewy pathology in anatomically interconnected regions, although the extent of
the neuroanatomical transmission of Lewy pathology was not thoroughly investigated. Lewy
pathology accumulation following intrastriatal fibril infusions resulted in progressive loss of
neurons in the substantia nigra, pars compacta, but not in the adjacent ventral tegmental area.
This novel approach recapitulates key features of Lewy bodies in human Parkinson’s disease
brains and establishes a mechanistic link between transmission of pathologic alpha-synuclein,
inclusion formation, and cell death (Luk et al., 2012a, Luk et al., 2012b). Thus, alpha-synuclein
pathology is sufficient to induce some of the behavioral and pathological features of sporadic
Parkinson’s disease.
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Table 1: Animal models of Parkinson’s disease
Model

Nigrostriatal
neurodegeneration
Toxin/Toxicant-Induced Models

Extranigral
pathology

Motor
symptoms

Non-Motor
Symptoms
Yes
(Dementia,
psychiatric,
GI
disorder)
Cognitive
deficit

Yes (dopaminergic cell
bodies in SN-and
dopaminergic terminal in
STR)

No

Yes

Methyl-4-phenyl-1,
2,3,6
tetrahydropyridine
(MPTP)
Lipopolysaccharide
(LPS)
Proteasome inhibitors

Yes (dopaminergic cell
bodies in SN-and
dopaminergic terminal in
STR)
Yes (dopaminergic cell
bodies in SN)

Yes (Locus
coeruleus)

Yes

Yes (VTA)

Yes

Carbobenzoxy-lisoleucyl-γ-t-butyl-lglutamyl-l-alanyl-lleucinal (PSI)
MG132

Yes (dopaminergic cell
bodies in SN-and
dopaminergic terminal in
STR)
Yes (dopaminergic cell
bodies in SN-and
dopaminergic terminal in
STR)

Yes (VTA)

Yes (dopaminergic cell
bodies in SN-and
dopaminergic terminal in
STR)
Yes (dopaminergic cell
bodies in SN-and
dopaminergic terminal in
STR)
Yes (dopaminergic cell
bodies in SN-and
dopaminergic terminal in
STR)

Yes (Locus
coeruleus)

6-hydroxydopamine
(6-OHDA)

Animal
Species

Disadvantages

Citation
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Rat,
Mouse

Acute,
intracerebral

(Hisahara and
Shimohama, 2010,
Tieu, 2011, Blesa et
al., 2012)

Rat,
Mouse,
nonhuman
primates
Rat,
Mouse

Acute,
hazardous

(Hisahara and
Shimohama, 2010,
Tieu, 2011, Blesa et
al., 2012)
(Qin et al., 2007)

No

Rat,
Mouse

Acute,

intracerebral

Cocaine
Reward
Memory
Retrieval

Rat,
Mouse

Not
determine
d

GI disorder

Rat,
Mouse

Acute,
hazardous

Not determined

Not
determine
d

Decrease in
GI motility

Rat,
Mouse

Acute,
hazardous

Yes (neocortex,
amygdala,
frontal cortex,
Hippocampus.)

Yes

NO

Mouse,
Rat

Time
dependent.

Yes (VTA)

Yes

Cognitive
deficit

Flu-like
symptoms

Acute,
intracerebral

(Bukhatwa et al.,
2009, Xie et al., 2010)

(Xie et al., 2010, Ren
et al., 2013)

Pesticide/Herbicide
Paraquat

Rotenone

Pathological alphasynuclein fibrils

(Hisahara and
Shimohama, 2010,
Tieu, 2011, Blesa et
al., 2012)
(Hisahara and
Shimohama, 2010,
Tieu, 2011, Blesa et
al., 2012)
(Luk et al., 2009, Luk
et al., 2012a, Luk et
al., 2012b)

Animal models have led us to a deeper understanding of the pathogenesis of Parkinson’s disease.
The animal models of Parkinson’s disease have accelerated the discovery of novel treatments for
the motor symptoms of Parkinson’s disease. The majority of Parkinson’s disease cases are
known to be sporadic. Here, we have discussed the weaknesses and strengths of the most
common in vivo non-transgenic models of Parkinson’s disease. These models include
neurotoxins, pesticides/herbicides, as well as the recent use of alpha-synuclein fibrils to induce
Parkinson’s-like Lewy pathology and/or dopaminergic neurodegeneration. However, none of
these models can fully recapitulate the complexity of human Parkinson’s disease. It is likely that
Parkinson’s disease has both genetic and environmental roots. Therefore, future models may
involve a combination of neurotoxin-induced and genetically induced Parkinson’s disease. It is
also important to consider using aged animals to increase their predictive validity.

Protective molecules implicated in protection against Parkinson’s disease: Glutathione and its
precursor N-acetyl-L-cysteine

As mentioned earlier, neurodegenerative disorders such as Parkinson’s disease are characterized
by oxidative stress. Under physiological conditions, oxidative stress is effectively handled by
endogenous antioxidant defenses within the cell. Glutathione is the most abundant antioxidant in
the brain and is found in millimolar concentrations is most cells (Pocernich and Butterfield,
2012). Glutathione is synthesized in both neurons and glia and detoxifies oxidants and
electrophiles (Griffith, 1999, Dringen, 2000, Dickinson and Forman, 2002). Under pathological
conditions, excessive production of reactive oxygen species and depletion of glutathione elicits
oxidative damage (Dias et al., 2013).
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The glutathione precursor N-acetyl-L-cysteine (NAC) was recently tested on Parkinson's patients
as a neuroprotective compound (Monti et al., 2016). In this study, NAC increased dopamine
transporter binding and improved UPDRS motor deficit scores, but the sizes of the effects were
relatively small (~10%) and the sample size was small. NAC can also elicit protection in
glutathione-independent manners in cellular models (Jiang et al., 2013; Posimo et al., 2013;
Unnithan et al., 2012; Unnithan et al., 2014). Recently, the Leak lab has shown that NAC may
also facilitate a stress-induced increase in heat shock protein 70 (Hsp70) in cellular models of
neurodegeneration (Jiang et al., 2013). Thus, in the present project, we hypothesize that
treatment with NAC may reduce proteotoxic and oxidative stress in experimental Parkinson's
disease. This subject will be discussed further in the chapter 2 of this dissertation.

Protective

molecules

implicated

in

protection

against

neurodegeneration:

dehydroepiandrosterone sulfate

Neurosteroids play a crucial role in the proper functioning of the central and peripheral nervous
systems, and help regulate neurotransmitter systems, promote neuronal viability, improve
myelination, and control cognitive processes (Paul and Purdy, 1992, Mathis et al., 1994, Meziane
et al., 1996, Maurice et al., 1998, Akwa et al., 2001). The term neurosteroid refers to steroid
hormones that can be synthesized both in brain and/or endocrine glands, either de novo from
cholesterol or by in situ metabolism of circulating hormones that accumulate in the nervous
system independent from steroidogenic gland secretion rates (Baulieu, 1997, Wojtal et al., 2006).
Dehydroepiandrosterone sulfate (DHEAS) is the sulfated ester of the neurosteroid
dehydroepiandrosterone (DHEA). DHEAS and DHEA are two of the most abundant
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neurosteroids synthesized within the nervous system (Flood et al., 1988, Migues et al., 2002).
Physiological concentrations of DHEA and DHEAS are maintained by the enzymes steroid
sulfates and sulfuryl transferase in the peripheral tissues, as well as in the brain (Babalola et al.,
2012). The levels of these two abundant adrenal steroids decrease with age in both men and
women (Schumacher et al., 2003). The link between reduced levels of DHEAS and
neurodegenerative diseases is still a controversial issue. However, some studies suggested that
the levels of DHEAS are significantly reduced in the brains of patients with Alzheimer’s disease
compared with healthy individuals (Nasman et al., 1991, Leblhuber et al., 1993, Solerte et al.,
1999, Murialdo et al., 2000). In vivo studies in rats using microdialysis suggest that
intraperitoneal injections of DHEAS induce hippocampal acetylcholine release, which is an
important neurotransmitter in cognitive function (Rhodes et al., 1996). Furthermore, inhibition of
steroid sulfatase increases DHEAS levels by preventing its conversion back to DHEA, and
facilitates the memory-enhancing effects of DHEAS (Johnson et al., 1997, Li et al., 1997,
Johnson et al., 2000). Other studies have also demonstrated that DHEAS protects hippocampal
neurons against glutamate-induced neurotoxicity in the hippocampus while little protection is
obtained from the equivalent doses of DHEA (Mao and Barger, 1998). These results suggest
that DHEAS is a neuroprotective agent with the potential to alleviate dementia associated with
Lewy body disorders. This subject will be discussed further in the chapter 3 of this dissertation.
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Materials and Methods

Animals and surgeries

All animal housing, treatments, and procedures were in accordance with the NIH Guide and
approved by the Duquesne University Institutional Animal Care and Use Committee. Male
Sprague Dawley rats were purchased from Hilltop Lab Animals (Scottdale, Pennsylvania). Male
CD1 mice from Charles River (Horsham, PA) were bred in the Duquesne animal care facility
and housed in a 12:12 photoperiod with ad libitum access to food and UV-disinfected water. On
the day of surgery, animals were anesthetized with 2–3% vaporized isoflurane in 3% oxygen and
stabilized in a stereotaxic frame.

Proteasome inhibitors: Male mice (3 months old) were infused with proteasome inhibitors
MG132 (0.25 μg in 0.5 μl, 0.5 μg in 1 μl , 1 μg in 2 μl, 3.75 μg in 3 μl) or lactacystin (0.25 μg
in 0.25 μl, 0.5 μg in 0.5 μl, 1 μg in 1 μl, 2 μg in 2 μl) or 1 μl vehicle into the hippocampus (ML
−2.0 mm, AP −2.5 mm, and DV −2.7 mm from skull) with a Hamilton syringe (80085,
Hamilton, Reno, NV) over the course of 4 min, followed by a 4 min rest period prior to removal,
to minimize diffusion into dorsal structures during withdrawal. Animals were perfused 7 days
post-injection.

Alpha-synuclein: Male mice (3 months old) were infused with preformed alpha-synuclein fibrils
of wild-type mouse origin, as described previously (Luk et al., 2012a) (5 μg in 1 μl, 6.25 μg in
1.25 μl, 12.5 μg in 2.5 μl, 25 μg in 5 μl) or 1 μl vehicle into the hippocampus (ML −2.0 mm, AP
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−2.5 mm, and DV −2.7 mm from skull) and perfused 30 or 90 days post-injection. For this
experiment, the fibrils were sonicated with the probe sonicator (Misonix model XL2020,
Misonix incorporated, Farmingdale NY), 60 pulses each for 0.2 sec.
Male rats (3 months old) were infused with 2 μg in 0.4 μl fibrils or 0.4 μl vehicle into the
striatum (ML ±3.0 mm, AP +0.20 mm, and DV −4.0 mm from skull) and/or hippocampus (ML
±2.7 mm, AP −4.5 mm, and DV −3.2 mm from skull) bilaterally over the course of 4 min
followed by a 4 min rest period. For this experiment, the fibrils were sonicated in the waterbathsonicator (FS15 ultrasonic cleaner, Thermo Fisher Scientific incorporated, Waltham, MA) for 60
sec.

FluoroGold and 6-OHDA: Male CD1 mice (3 months old) were injected with FluoroGold (6 μg
in 0.4 μL), 6-OHDA (4 μg in 1.6 μL) or an equal volume of vehicle into the caudoputamen (ML
−2.0 mm, AP +0.5 mm, and DV −3.2 mm from bregma). For the studies using FluoroGold, the
tracer was delivered one week before 6-OHDA infusions in the same striatal location to
retrogradely label the nigrostriatal pathway. The doses chosen for 6-OHDA and FluoroGold are
consistent with other reports (Liang et al., 2008, Cohen et al., 2011, Lazzarini et al., 2013, Bagga
et al., 2015) and did not lead to any overt tissue necrosis at the injection site.

Animals were placed on a heating pad until resumption of spontaneous locomotor activity and
then returned to their cages until sacrifice. All animals received 0.015 mg/kg buprenorphine
subcutaneously during recovery from surgery and lidocaine and antibiotic treatment of the scalp
wounds.
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NAC: In the NAC experiments, mice received 100 mg/kg NAC in PBS or an equal volume of
vehicle (4.44 mL/kg body weight or 0.176 mL per 40 g mouse) as a daily intraperitoneal
injection using an insulin syringe (309311, Becton Dickinson, Franklin Lakes, NJ). These daily
injections were initiated on the day of the 6-OHDA surgeries, immediately after the surgeries
were completed. At the end of the experiment, animals were reanesthetized with isoflurane and
perfused through the left ventricle with 50 mL of saline followed by 100 mL of 4%
paraformaldehyde (9990244, Thermo Scientific, Kalama- zoo, MI) in 0.1 M phosphate buffer.

DHEAS: In the DHEAS experiments, animals received 10 mg/kg DHEAS in PBS or an equal
volume of vehicle (1 mL/kg body weight or 0.4 mL per 400 g rat) intraperitoneally using an
insulin syringe immediately before the novel object/place recognition tests. At the end of the
experiment, animals were reanesthetized with isoflurane and perfused through the left ventricle
with 100 mL of saline followed by 200 mL of 4% paraformaldehyde in 0.1 M phosphate buffer.

Chemicals and antibodies

Primary and secondary antibodies and their dilutions are listed in supplementary Tables 3 and 4
in the Appendix. Omission of primary antibodies from the assays always resulted in loss of
signal. Proteasome inhibitors MG132 (474790, EMD Millipore, Billerica MA) and lactacystin
(AdipoGen Corporation, San Diego, CA) were stored at – 20 and – 80 oC, respectively, as 10
mM stock solutions in dimethyl sulfoxide (DMSO).

6-OHDA was purchased from Sigma-Aldrich (H116-5MG, Sigma-Aldrich, St. Louis, MO) and
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stored at a concentration of 2.5 mg/mL at −20 °C until use. FluoroGold was purchased from
FluoroChrome (Fluorochrome LLC, Denver, CO) and stored at a concentration of 1.5% in PBS
at 4 °C until use.
NAC was purchased from Acros Organics (160280250, Acros Organics, Morris, NJ), dissolved
in phosphate-buffered saline (PBS), sterile-filtered, and stored at a concentration of 22.5 mg/mL
at −20 °C until use.
DHEAS was purchased from Sigma-Aldrich (D5297-1G, Sigma-Aldrich, St. Louis, MO) and
prepared at a concentration of 10 mg/mL on the day of the experiment by dissolving in
phosphate-buffered saline (PBS) and sterile-filtered before injections.

Histology

Perfused brains were immersed in 30% sucrose in 10 mM PBS for 48 h and cut on a freezing
microtome in the coronal or sagittal plane. Free-floating sections (50 μm) were stored in
cryoprotectant at − 20 °C until immunostaining was performed. Cryoprotectant was rinsed off
with three exchanges of PBS and sections were then incubated in a 1:1 solution of Odyssey
Block (LI-COR Bioscience, Lincoln, NE) in PBS for 1 h at room temperature on a shaker.
Sections were subsequently incubated in primary antibodies at the concentrations listed in Table
3 for 24–48 h on a shaker at 4 °C. Secondary antibodies were applied to tissue for 1h at room
temperature with gentle agitation. Primary and secondary antibodies were both added to a 1:1
solution of Odyssey Block in PBS with 0.3% Triton X-100. Animals injected with 6-OHDA
were perfused 7 or 10 days post-injection and brains were immunostained for tyrosine
hydroxylase (TH)+ dopaminergic terminals in the striatum. Animals injected with alpha29

synuclein were perfused 30 or 90d post-injection and brains were immunostained for the
neuronal marker NeuN, the astrocyte marker glial fibrillary acidic protein (GFAP),
pathologically phosphorylated alpha-synuclein (pSer129), and K48-linked ubiquitin. Unbound
primary antibodies were rinsed off with three exchanges of PBS and sections were then
incubated in the appropriate fluorescent secondary antibodies as indicated in Table 4, for 1 h on
a shaker at room temperature. Hoechst 33258 (bisBenzimide) was added during the secondary
incubation at a concentration of 0.005 μM to label nuclei, except in animals that received
FluoroGold (which also fluoresces under UV illumination). Nuclei were also labeled with the
infrared marker DRAQ5 (1:10,000 or 0.5 μM, Biostatus, Leicestershire, UK). Following six
washes in PBS, sections were mounted onto glass slides (Superfrost Plus, Fisher Scientific,
Pittsburgh, PA) and coverslipped with FluoroMount G (Southern Biotech, Birmingham, AL).
Sections were scanned on an infrared Odyssey Imager for lower resolution analyses (21 μm
resolution) or under epifluorescent microscopy (Olympus IX73, B&B Microscopes, Pittsburgh,
PA) for higher resolution microscopy in the visible wavelengths, using objectives with
magnification ranging from 4× to 100×.

For the (3,3'-diaminobenzidine (DAB) immunohistochemistry, sections were pretreated with 1%
hydrogen peroxide for 15 minutes, followed by three exchanges of PBS. Non-specific antibody
binding was minimized by incubating for one hour in 5% bovine serum albumin (A30075-100G,
Research Products International Corp, Mt Prospect, IL) and 0.3% Triton-X 100 (Sigma) on a
rotator at room temperature. This was followed by overnight mouse anti-TH primary antibody
incubation on a rotator at room temperature. The next day, biotinylated anti-mouse secondary
antibodies (PK6102, Vector Labs, Burlingame, CA) were applied (120 minutes on rotator at 24°
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C) and followed by application of the Vectastain Elite ABC horseradish peroxidase reagents
(PK6102, Vector Labs, Burlingame, CA). Following a 5 minute preincubation in
diaminobenzidene (0.05% solution in Tris Buffer, pH 7.2) (D5905-50TAB, Sigma-Aldrich, St.
Louis, MO), hydrogen peroxide was added to begin the peroxidase reaction (final dilution 3%)
and terminated by buffer washes within 20 minutes. Sections were then washed, mounted,
dehydrated in a graded series of ethanols, cleared in xylenes, and coverslipped with Permount
(Fisher Scientific, Pittsburgh, PA). Immunolabeling was studied using a light microscope
(Olympus BX41, B&B Microscopes, Pittsburgh, PA).

Thioflavin staining

Thioflavin S staining was used to measure insoluble and aggregated Lewy-like pathology, as
previously published (Paumier et al., 2015, Mason et al., 2016). Briefly, sections were mounted
onto glass slides and dried. Slides were then immersed in 10 mM PBS (5 min), followed by
0.05% KMnO4 / PBS (20 min). Following two rinses in PBS (2 min each), sections were
immersed in 0.2% K2S2O5 / 0.2% oxalic acid / PBS for 1 min. After five PBS rinses (2 min
each), slides were immersed in freshly filtered 0.0125% Thioflavin S / 40% EtOH / 60% PBS for
3 min in the dark. This was followed by immersion in 50% EtOH / 50% PBS (10 min), followed
by four rinses in PBS (5 min each). Next, nuclei were stained with the Hoechst reagent (0.003
μM; Hoechst 33258, bisBenzimide) in 0.3% Triton X-100, followed by a final 5-min rinse in
water. Stained sections were then dried and coverslipped and viewed with epifluorescent
microscopy (Olympus IX73, Pittsburgh PA).
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Image analyses

For the infrared measurements of tyrosine hydroxylase (TH) levels, regions of interest were
traced in three sections by a blinded observer along the boundaries of the striatum, using the
anterior commissure, lateral ventricle, and corpus callosum as anatomical landmarks. For the
measurements of nigral TH or FluoroGold levels, the nigra was defined by the dorsal boundaries
of the TH immunostaining, the lateral boundaries of the ventral tegmental area, and the
ventrolateral outer surface of the brain. The ventral tegmental area was distinguished from the
substantia nigra by the location of the medial terminal nucleus and the medial lemniscus. For the
bilateral cell counts in the substantia nigra, images of the ipsilateral and contralateral nigrae were
stitched on the Olympus microscope and a blinded observer counted all nigral TH+ cells in three
ventral midbrain sections per animal using the manual count tool in ImageJ software (NIH
Image, Bethesda, MD). For the infrared measurements of NeuN levels, regions of interest were
traced in three sections by a blinded observer along the outer boundaries of the hippocampus.
Photographs from all experimental groups were captured at the same exposures and with the
same intensity scaling. The cell counts of two independent and blinded raters were always found
to be in agreement. Finally, sections from FluoroGold-infused animals were viewed under
confocal microscopy to assess colocalization of FluoroGold with TH (Olympus Fluoview 1200
confocal system on an IX83 inverted frame). All confocal images were captured using a 40×
silicone oil objective (NA 1.25) with a gain of 1.0. In the confocal studies, the UV-illuminated
FluoroGold staining was pseudocolored red to contrast with the green TH. Higher resolution
epifluorescent images were captured with 40× or 100× objectives. Sections from control and
experimental groups were processed, photographed, and analyzed in parallel.
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Blocking peptide experiments

Preadsorption controls were employed to confirm the specificity of the primary antibodies
against pathologically phosphorylated alpha-synuclein (pSer129). Preadsorption controls are not
useful for monoclonal antibodies, as they always will be adsorbed out by their antigen leading to
inevitable loss of labeling regardless of which proteins they bind in tissue (Saper, 2005). Thus,
we incubated the polyclonal pSer129 with 10-fold excess blocking peptide (Cat.no. 188826,
Abcam, Cambridge, MA) for 24h at 4 oC prior to application to tissue. Adjacent sections from
the same animals were exposed to free primary antibodies or blocked primary antibodies for 24h
at 4 oC, followed by secondary antibody incubations. To control for secondary antibody
specificity, primary antibodies were omitted from the immunohistochemical protocol, and this
led to loss of fluorescent signal as expected.

Behavioral testing: Novel object (NOR) and novel place recognition (NPR) tests

Object and place recognition tasks consisted of four phases including an initial acclimation
(habituation) phase of 10 minutes conducted in an open-field arena (45 cm × 60 cm × 60cm)
constructed of green polyvinylchloride plastic. Three identical floors were prepared—a bare
floor that was used during the acclimation phase, and two identical floors that contained brackets
to fix objects into place. A dim diffusive light from two lamps was utilized to minimize shadows
within the field. A video camera (JVC) was positioned over the arena to record behavior during
the retention phases for subsequent analysis by blinded observers. The stimulus objects were
made of glass or plastic with different shapes and textures, such as light bulbs, mugs, coffee
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cups, and saline bottles. The animals were not able to displace the objects or hide in or under
them. Also, objects were selected that did not have accessories that could stimulate play
behaviors such as handles. Objects were washed with 70% isopropyl alcohol to remove olfactory
cues between trials.

The acclimation phase was followed 24 h later by a familiarization phase, during which the
animals were exposed to two identical objects in fixed in opposite corners of the arena 10 cm
distant from the adjacent walls. The familiarization phase lasted 5 minutes for the animals to
acquire recognition memories of the objects and their locations within the arena. Twenty-four
hours later, recognition testing took place over a 5 min period, during which the animals were
allowed to explore both the familiar object from the previous phase and a novel object that was
substituted for one of the identical familiar objects. The time animals spent exploring the familiar
and novel objects was recorded. The head of the animal must be within 4 cm and oriented within
45 degrees of the object to be considered engaged in object exploration.

Twenty-four hours later, the animals were returned to the arena for an additional trial to
investigate the ability of the animal to recognize the novel place. The arena contained the two
identical familiar objects from the familiarization phase, but one object was moved to a different
location out of the corner and farther toward the center of the arena. The exploration time for
each object place was recorded. Exploration ratio was calculated by dividing the time animal
spent exploring the novel object/place by the total time exploring both the novel and familiar
objects/places. Results were reported as mean ± SEM. Animals that spent a total of less than 10
sec exploring objects during the testing phases were excluded from the data analysis.
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Behavioral testing: Buried Pellet Test

The buried peanut test was performed to measure olfactory function, as previously described in
the literature (Lehmkuhl et al., 2014). Briefly, mice were habituated for one hour prior to all test
days. During habituation, the animal was placed in a cage with evenly distributed clean bedding
for an hour. Next, the animal was placed in a new cage in which a peanut was hidden 0.5 cm
below the bedding so that it is not visible. The latency to find a buried peanut immediately
following entry into a clean mouse cage was videotaped and measured by a blinded observer.

Statistical analyses

Data are presented as the mean and SEM in all figures. Depending on the number of independent
variables, data were analyzed by one, two, or three-way ANOVA followed by the Bonferroni
post hoc correction (SPSS Version 20, Armonk, NY). When there were only two groups, the
two-tailed, unpaired Student's t test was performed. Differences were reported significant only
when p ≤ 0.05. The Grubb's outlier test did not reveal any significant outliers. The MannWhitney U test was employed for the inclusion count measurements due to heterogeneity of
variance. The Pearson correlation was performed to compute correlation between inclusion
counts and behavioral functions. The unpaired Student’s t test was employed for the behavioral
analysis.
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Chapter 1
Rationale

The glutathione precursor NAC has been shown to be protective in multiple experimental models
of injury and to benefit patients with various neurological conditions, ranging from Parkinson’s
and Alzheimer’s disease to traumatic brain injury, schizophrenia, and bipolar disorder (Adair et
al., 2001, Berk et al., 2008a, Berk et al., 2008b, Hoffer et al., 2013). NAC increases glutathione
levels in the brain of patients with Parkinson's disease, supporting the view that NAC can cross
the blood-brain barrier (Holmay et al., 2013, Katz et al., 2015). Recently, the Leak lab has shown
that NAC may also facilitate a stress-induced increase in heat shock protein 70 (Hsp70) in
cellular models of neurodegeneration (Jiang et al., 2013). As discussed further below, NAC may
raise Hsp70 expression through thiol exchanges with heat shock factor 1, which contains
multiple cysteine residues and facilitates Hsp70 gene transcription. Hsp70 is known to promote
proteasomal degradation of oxidized proteins by binding to oxidized proteins and mediating their
interaction with the 20S proteasome (Reeg et al., 2016). NAC therefore appears to protect
neuronal and glial cells through both glutathione-dependent and independent manners. In order
to define the mechanism of action of NAC in an animal model of neurodegeneration, the first
goal of the present study was to establish an in vivo model of the protective effects of NAC.
Before we could test the hypothesis that NAC is protective against neurodegeneration, we had to
establish a robust and reproducible animal model of neurodegeneration.

Multiple models were examined because no one model can mimic all the pathologies of such a
complex disorder and every model suffers from unique limitations. Furthermore, if a
neuroprotectant can ameliorate multiple types of injury, it is far more likely to succeed in the
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clinic. Our models included: 1) proteasome inhibitor infusions into the mouse hippocampus to
inhibit the degradation of misfolded proteins and elicit cell death, 2) alpha-synuclein fibril
infusions into the mouse and rat hippocampus and/or striatum to seed the misfolding of
endogenous alpha-synuclein into Lewy bodies and Lewy neurites, and 3) 6-OHDA infusions into
the mouse striatum to elicit oxidative stress and kill dopaminergic neurons.

Proteotoxic stress from protein misfolding is a central feature of neurodegenerative diseases and
can lead to hallmark protein inclusions (Morimoto, 2008). For example, both Parkinson’s and
Alzheimer’s disease are characterized by protein inclusions in the hippocampus (Goedert et al.,
2010). Lewy pathology in the hippocampal and entorhinal cortex, first observed in Braak stages
3 or 4, have profound implications for cognitive dysfunction in Parkinson’s patients (Braak et al.,
2003a, Russell et al., 2014) Therefore, we first sought to develop animal models of hippocampal
proteotoxicity using the proteasome inhibitor lactacysytin and alpha-synuclein fibrils.

6-OHDA has been used to model nigrostriatal cell loss for many decades. Recent studies have
relied on immunostaining for the dopaminergic marker TH to confirm dopaminergic cell death.
However, TH mRNA and protein levels are well known to be subject to modulation by stress
(Baruchin et al., 1990, Kumer and Vrana, 1996, Chang et al., 2000, Tank et al., 2008, Tekin et
al., 2014). There are limitations to relying only on TH expression by itself, because changes in
TH expression can occur independently of changes in actual dopaminergic cell numbers.
Therefore, the retrograde tract tracer FluoroGold was used to specifically label nigrostriatal
projection neurons, which form the pathway known to degenerate in Parkinson’s disease.
FluoroGold is an exogenous molecule and therefore not subject to stress-induced changes in

37

gene transcription. However, the use of FluoroGold as a tracer in the 6-OHDA model has not
been properly validated.

Specific Aim 1:

Establish the 6-OHDA model of Parkinson's disease and validate the tools used

to define nigrostriatal degeneration in vivo. Test the hypothesis that FluoroGold does not change
the impact of 6-OHDA toxicity on loss of nigrostriatal somata and terminals. Test the hypothesis
that retrograde tract-tracing is a more sensitive tool to quantify nigrostriatal degeneration than
TH+ cell loss. Examine whether relatively high-throughput screening of FluoroGold or TH levels
on an infrared 16-bit imager can serve as an initial screen for nigrostriatal pathway loss.
Results
Develop a model of proteotoxic stress in the mouse hippocampus in vivo

Male CD1 mice were infused with the proteasome inhibitors MG132 and lactacystin in the
hippocampus. Animals were perfused 7 days post-injection and stained for NeuN+ neurons and
GFAP+ astrocytes. Sections were imaged at high resolution on an EVOS microscope or at low
resolution on an Odyssey Infrared Imager. First, we showed loss of immunofluorescent signal
when primary antibodies were omitted (Figure 3), revealing the specificity of the secondary
antibodies. The primary antibodies also result in single bands at the expected molecular weight
on Western blots and stain cellular structures consistent with the appearance of neuronal nuclei
(NeuN) or stellate astrocytes (GFAP).

38

Fig. 3. Hoechst-GFAP-NeuN triple staining in the hippocampus. Coronal brain tissue from male CD1 mice was
collected and stained with antibodies against NeuN and GFAP and the nuclear marker Hoechst. NeuN antibodies
labeled neuronal nuclei and GFAP antibodies labeled reactive astrocytes as expected. Omission of primary antibody
caused the expected loss of signal.

Proteotoxicity induced by MG132 and lactacystin

Although we tried to infuse MG132 into the mouse hippocampus, we discovered that MG132
failed to dissolve in PBS or DMSO followed by addition of PBS. Pure DMSO infusions into the
rodent brain can lead to toxicity (Hanslick et al., 2009). Therefore, we abandoned MG132 and
infused lactacystin, which is readily dissolved in PBS.
We discovered that infusions of 5-10 μg lactacystin elicited severe loss of NeuN in the ipsilateral
hippocampus in vivo (Figure 4). However, lactacystin was too toxic in a small fraction of the
animals, and led to tissue necrosis and a hole in the hippocampus. It was therefore abandoned as
a model of hippocampal neurodegeneration.
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Fig. 4. Lactacystin elicits gliosis and loss of NeuN. The dorsal hippocampus was infused with phosphate buffered
saline (PBS) or the proteasome inhibitor lactacystin (10 μg) in adult mice (top). Animals were killed after 7d and
sections stained for NeuN and GFAP and imaged on an infrared Odyssey imager. Hippocampal NeuN + signal was
quantified in Odyssey software. N=10 mice per group. *p≤0.001 vs 0 μg lactacystin, Bonferroni post hoc following
two-way ANOVA.

Chronic proteotoxic stress from the fibrillized protein alpha-synuclein

As lactacystin was overly toxic to a small fraction of animals at ED50 doses, we decided to
employ the alpha-synuclein fibril model instead. Hippocampal neurons are known to develop
dense alpha-synuclein+ Lewy pathology in Parkinson's disease and Lewy body dementia (Braak
et al., 2003a, Russell et al., 2014). Previous studies have shown that injections of alpha-synuclein
fibrils into CA1 of the hippocampus lead to Lewy-like pathology in areas that project to the
hippocampus (Luk et al., 2012a, Sacino et al., 2013). However, those infusions were unilateral
and failed to lead to cognitive deficits, perhaps because the unlesioned hemisphere could
compensate against the unilateral injury. Therefore, we began this study by infusing the
hippocampus with fibrils. Mice injected with alpha-synuclein fibrils were perfused 30d postinjection and brains were immunostained for the neuronal marker NeuN and the astrocyte marker
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GFAP. There was mild loss of NeuN following infusion of 12.5μg fibrils (Figure 5), but the
response was slight and not highly dose-dependent. In this study we used higher doses of alphasynuclein fibrils compared to the literature, in which 5 μg fibrils were infused in 2.5 μl PBS (Luk
et al., 2012a). However, our goal was to accelerate and increase the spread of alphasynucleinopathy to model the cognitive deficits of dementia with Lewy bodies.

Fig. 5. Alpha-synuclein fibrils elicit mild loss of
NeuN signal in the ipsilateral hippocampus. The
dorsal hippocampus was stereotaxically infused with
phosphate buffered saline (PBS) or α-synuclein fibrils
in adult mice. Animals were killed after 1 month.
Brain sections were stained for NeuN and GFAP and
imaged on an infrared imager. Hippocampal NeuN +
signal was quantified in Odyssey software by a
blinded observer. N=10 mice per group. *p≤0.001 vs 0
μg α-synuclein, Bonferroni post hoc following twoway ANOVA
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Formation of Lewy-like pathology following infusions of alpha-synuclein fibrils

Mice were infused with alpha-synuclein fibrils or PBS into the hippocampus. One month later,
coronal brain sections from both groups were immunostained in parallel for pathologically
phosphorylated alpha-synuclein (pSer129) and imaged at the same exposure and intensity scaling
(Fujiwara et al., 2002, Anderson et al., 2006). Nuclei were labeled blue with Hoechst. As
expected, alpha-synuclein fibrils elicited Lewy-like inclusions in the mouse hippocampus in a
dose-dependent manner (Figure 6).

Fibril infusions into the hippocampus led to dense

accumulations of pSer129+ inclusions in CA1, CA2, and the dentate gyrus. Lewy-like inclusions
were formed within neurites and somata (Figure 7). However, the pathology was sparse and was
not transmitted to afferent or efferent sites that project to or are innervated by the hippocampus.
At this time, we had not yet discovered that increasing the duration of sonication greatly
facilitates the transmission of Lewy pathology across the brain. For this reason, we decided to
use the well-established 6-OHDA model of nigrostriatal cell loss in order to test the mechanism
of action of NAC.
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Fig. 6. Alpha-synuclein fibrils elicit Lewy-like inclusions in the mouse hippocampus. Mice were infused with the
indicated doses of alpha-synuclein fibrils or monomers and sacrificed 1 month later. Hippocampal sections were
immunostained for phosphorylated alpha-synuclein (pSer129), a modification associated with Lewy pathology.
Lewy-like pathology was elicited in a dose-dependent manner as expected. Hoechst labeling of nuclei is shown in
blue.
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Fig. 7. Alpha-synucleinopathy following fibril injections. Mice were infused with 5 ug alpha-synuclein fibrils or
monomers and sacrificed 1 month later. Coronal brain sections were collected and immunostained for pathologically
phosphorylated alpha-synuclein (pSer129). Nuclei were labeled with Hoechst. The fibril injection in this animal
extended from CA1 into CA2 and the dentate gyrus (DG). Dense Lewy-like pathology was elicited by one month
post-infusion.

Impact of the retrograde tracer FluoroGold on 6-OHDA toxicity in the striatum

As mentioned earlier, the phenotypic marker TH is known to be modulated by stress (Baruchin et
al., 1990, Kumer and Vrana, 1996, Chang et al., 2000, Tank et al., 2008, Tekin et al., 2014). As a
result, loss of TH may not reflect true loss of dopaminergic terminals or cell bodies. In order to
address this potential confound, we infused the retrograde tracer FluoroGold into the striatum to
label dopaminergic cell bodies in the ipsilateral substantia nigra, pars compacta. We expected 6OHDA-induced loss of FluoroGold in the nigra to be a more sensitive measurement of
dopaminergic cell death than measurements relying on TH, as only those terminals that project to
the infusion site would be retrogradely labeled. In contrast, measurements of all TH+ neurons in
the nigra would include those neurons that do not project to the center of the injection and are not
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killed by the circumscribed 6-OHDA infusions. Furthermore, in contrast to TH, FluoroGold is
not an endogenous protein and loss of FluoroGold immunoreactivity is expected to reflect true
loss of dopaminergic cell numbers (Sauer and Oertel, 1994). Thus, we began this study by
validating the use of this retrograde tracer (Fig.8A). Infusions of FluoroGold into the striatum
retrogradely labeled neurons in the substantia nigra, pars compacta as expected. Next, we infused
FluoroGold or vehicle into the striatum one week before 6-OHDA, at the same stereotaxic
coordinates. This protocol permitted tracer uptake without any disruption from 6-OHDA-induced
oxidative stress. The dose of 6-OHDA (4 ug) was based on a pilot study showing ~50% loss of
dopaminergic terminals (not shown). As an initial screen for 6-OHDA-induced loss of the
nigrostriatal pathway, we measured TH and FluoroGold label in both the ipsi and contralateral
striata and nigra using an infrared Odyssey imager (Fig. 8 and 9). The results reveal a slight but
significant loss in ipsilateral TH levels in the vehicle-treated striatum in the absence of
FluoroGold, as shown in the first two bars in Figure 8B. Importantly, FluoroGold did not alter
the impact of 6-OHDA on striatal TH loss. This finding suggests that FluoroGold can be used in
conjunction with 6-OHDA with no alteration in its toxic effects. However, FluoroGold infusions
led to a slight decrease in striatal area in the contralateral hemisphere (Fig. 8C). This effect was
not apparent in the 6-OHDA group, possibly due to astrocytosis or some other form of
hypertrophy or hyperplasia in response to loss of dopaminergic terminals. Finally, the most
important measurement—TH expression as a function of striatal area—showed no significant
impact of FluoroGold in any group (Fig. 8D).
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Fig. 8. Impact of the retrograde tracer FluoroGold on 6-OHDA toxicity in the striatum. (A) Mice were
stereotaxically infused with 6 μg FluoroGold (FG). Seven days later, mice were sacrificed and brain sections viewed
under UV illumination on an epifluorescent microscope. The ipsilateral nigrostriatal pathway was retrogradely
labeled. cc, Corpus callosum; CPu, caudatoputamen; SNpc, substantia nigra, pars compacta; SNpr, substantia nigra,
pars reticulata. (B) In a separate series of experiments, mice were infused with 6 μg FluoroGold or an equivalent
volume of phosphate-buffered saline (PBS) into the right striatum. Seven days after FluoroGold infusions, mice
were infused with 4 μg 6-OHDA or an equivalent volume of vehicle (0.02% ascorbic acid in saline) in the same
striatal location. One week following 6-OHDA infusions, forebrain sections were immunostained for the
dopaminergic terminal marker tyrosine hydroxylase (TH) and FluoroGold and scanned on the Odyssey Imager. (b)
The impact of 6-OHDA toxicity on overall striatal TH levels was not affected by FluoroGold. (C) FluoroGold
slightly reduced striatal area in the hemisphere contralateral to the infusion. 6-OHDA prevented this effect. (D)
FluoroGold did not change TH levels per unit area in the striatum of vehicle or 6-OHDA-infused animals. (E)
Representative coronal sections through the forebrain, immunolabeled for TH + dopaminergic terminals (green) and
FluoroGold (red). Shown are the mean and SEM of 5–6 mice per group. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 versus
0 μg 6-OHDA; + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 ipsilateral versus contralateral; ~ p ≤ 0.05, ~~ p ≤ 0.01, ~~~ p

46

≤ 0.001 versus 0 μg FG; three-way ANOVA followed by Bonferroni post hoc correction. Copyright 2016 by
Nouraei et al 2016. Reprinted with permission.

Next, we focused on the ventral mesencephalon to investigate whether FluoroGold could alter
loss of nigral TH in response to 6-OHDA. Our results suggested that FluoroGold infusions did
not change TH expression in the nigra of 6-OHDA or vehicle-infused animals (Fig. 9A). We also
demonstrated that FluoroGold decreased nigral area in the 6-OHDA group (Fig. 9B). However,
FluoroGold had no effect on TH expression as a function of nigral area (Fig. 9C). As expected,
FluoroGold loss in the nigra in response to 6-OHDA toxicity was more dramatic than TH loss
(Fig.9D vs A, G). Cell counts confirmed that loss of FluoroGold+ cells was greater than TH+ cell
loss in the nigra (Fig. 9E vs F, H vs I). Thus, the FluoroGold tracer was a more sensitive tool to
measure the toxicity of 6-OHDA than measurements relying on expression of TH protein alone.
Damier and colleagues described the topographic pattern of nigral degeneration in patients with
Parkinson’s disease (Damier et al., 1999). Those studies revealed that the ventrolateral nigra is
the most vulnerable to dopaminergic cell loss in this condition. Our 6-OHDA model exhibited
the same pattern as in patients (see white arrows in Fig. 9H and I). Furthermore, we also showed
with a confocal analysis that some, but not all FluoroGold+ cells expressed the dopaminergic
marker TH, consistent with previous FluoroGold studies (Sauer and Oertel, 1994). It is possible
that FluoroGold uptake suppressed TH transcription or translation in nigrostriatal cells, as there
are previous reports showing that FluoroGold can exert mild toxicity (Naumann et al., 2000).
The colocalization studies also confirmed that the cells projecting to the dorsal neostriatum, the
epicenter of the infusion, were clustered in the ventral tier of the substantia nigra, pars compacta
(see merged images in Fig. 9G, J).
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Fig. 9. Impact of the retrograde tracer FluoroGold on 6-OHDA toxicity in the substantia nigra. Mice were
stereotaxically infused with 6 μg FluoroGold (FG) or an equivalent volume of phosphate-buffered saline (PBS) into
the right striatum. Seven days later, mice were infused in the same location with 4 μg 6-OHDA or an equivalent
volume of vehicle (0.02% ascorbic acid in saline). One week later, brain sections were stained for the dopaminergic
terminal marker tyrosine hydroxylase (TH) and FluoroGold. (A) The impact of 6-OHDA on overall TH levels in the
nigra was not affected by FluoroGold. (B) FluoroGold slightly reduced nigral area in both hemispheres of 6-OHDAinfused animals. (C) FluoroGold did not change TH levels per unit area in the nigra of vehicle or 6-OHDA-infused
animals. (D) Overall FluoroGold levels in the nigra were significantly reduced by 6-OHDA. (E) FluoroGold did not
significantly change TH+ cell counts in the nigra in vehicle or 6-OHDA-infused animals. (F) The number of
FluoroGold+ cells of the nigrostriatal pathway was significantly reduced by 6-OHDA. (G) Representative coronal
sections through the midbrain, immunolabeled for TH + dopaminergic neurons (green) and FluoroGold + cells (red)
and scanned on the Odyssey Imager. (H–I) Microscopic images of FluoroGold + (h) and TH+ (i) cells in the ventral
midbrain in 6-OHDA/saline and FluoroGold/PBS-infused animals. The arrow points to the lateral nigra, the area
most vulnerable to loss in Parkinson's disease. (J) Confocal analysis of FluoroGold and TH dual labeling. Arrows
point to some of the cells that contain both FluoroGold and TH. Asterisks overlie FluoroGold-labeled nigrostriatal
cells that do not express TH. FluoroGold+ cells were viewed under UV illumination and pseudocolored red for
presentation. Shown are the mean and SEM of 5–6 mice per group. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 versus 0 μg
6-OHDA; + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 ipsilateral versus contralateral; ~ p ≤ 0.05, ~~ p ≤ 0.01, ~~~ p ≤
0.001 versus 0 μg FG; three-way ANOVA followed by Bonferroni post hoc correction or two-tailed Student's t-test
for panels d and f. IPN, interpeduncular nucleus; ml, medial lemniscus; SNpc, substantia nigra, pars compacta;
SNpr, substantia nigra, pars reticulata; VTA, ventral tegmental area. Copyright 2016 by Nouraei et al. Reprinted
with permission.
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Discussion

In this aim, multiple models of Parkinson’s disease that mimic oxidative or proteotoxic stress
were developed in order to test the efficacy of neuroprotective molecules. This was
accomplished because no one model can mimic all different pathological aspects of a complex
disorder such as Parkinson’s disease. Importantly, if a neuroprotectant can ameliorate multiple
types of injury, it is far more likely to succeed in the clinic. The models established in this study
include the following: 1) proteasome inhibitor infusions into the mouse hippocampus to inhibit
the degradation of misfolded proteins and elicit cell death within 7 days, 2) 6-OHDA infusions
into the mouse striatum to elicit oxidative stress and kill dopaminergic neurons within 7-10 days,
and 3) alpha-synuclein fibril infusions into the mouse and rat hippocampus and/or striatum to
seed the misfolding of endogenous alpha-synuclein and elicit the formation of Lewy bodies and
Lewy neurites. We have fully reproduced the 6-OHDA model of Parkinson’s disease, a robust
and reproducible method of inducing dopaminergic neurodegeneration in a pattern that mimics
the topography of nigrostriatal cell loss in the human condition. Nigrostriatal degeneration was
verified by a blinded observer with four rigorous techniques: 1) measurements in overall TH
expression levels in both the striatum and nigra using the 16-bit Odyssey Imager and 2) TH+
nigral cell counts in large, high-quality stitched montages of the substantia nigra, 3)
measurements of FluoroGold levels using the Odyssey imager, and 4) counts of individual
FluoroGold+ nigral neurons in high-quality stitched images.
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We have found that FluoroGold is a more sensitive tool than measurements of either TH cell
numbers or TH levels, consistent with our original hypotheses. We have also gathered data
suggesting that FluoroGold exerts some mild toxicity, as evident in nigral area measurements,
but that it did not significantly affect the toxicity of 6-OHDA in either the striatum or the nigra.
Thus, we have validated the use of the 16-bit, high sensitivity Odyssey imager as an initial
screening tool to measure loss of the nigrostriatal pathway. The 16-bit depth (216) of the
grayscale Odyssey imager translates to a wide dynamic range, because 216 (65,536) potential
shades of gray afford high resolution, especially compared to 8-bit color imagers, which perceive
only 28 (256) shades of color. The overall TH level measurements in the striatum and nigra with
the Odyssey imager are in general agreement with higher resolution cell count data from stitched
images, which facilitates future studies of this pathway.

Finally, we were also able to report measurements of striatal and nigral area, which the majority
of Parkinson’s studies fail to show, even though striatal TH measurements are highly dependent
upon the size of the region of the interest (i.e., larger tracings result in higher TH values) and
changes in nigral and striatal area provide additional information about the toxicity of treatments.
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Chapter 2
Rationale

The glutathione precursor NAC has been shown to be beneficial in many clinical trials. For
example, NAC improved some aspects of cognition in patients with Alzheimer’s disease (Adair
et al., 2001). NAC increased the chances of symptom resolution form 42% to 86% (with no
reported side effects) in soldiers experiencing mild traumatic injury compared to those who
received placebo (Hoffer et al., 2013). NAC also has been shown to improve the depressive
component of bipolar disorder (Berk et al., 2008a) and to mitigate the negative symptoms and
akathisia associated with schizophrenia (Berk et al., 2008b). Recent studies have suggested that
administration of NAC increases glutathione levels in the brains of patients with Parkinson's
disease (Holmay et al., 2013, Katz et al., 2015). These findings support the view that NAC can
cross the blood-brain barrier in humans. Additionally the neuroprotective properties of NAC
have been investigated in Parkinson's patients (Monti et al., 2016). The results of this
preliminary study demonstrate that patients receiving the NAC showed a ~10% increase in
dopamine transporter binding in the caudate and putamen and improvements in the Unified
Parkinson’s Disease Rating Scale (UPDRS), a standardized measurement of clinical symptoms,
as compared to the placebo group.

NAC is one of the most frequently used positive controls in cellular and animal studies of
neuroprotection due to its well-established antioxidant properties. Recent studies in our lab
showed that NAC prevents neurodegeneration in multiple cellular models of neurodegenerative
disorders (Jiang et al., 2013; Posimo et al., 2013; Unnithan et al., 2012; Unnithan et al., 2014).
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Consistent with these observations, Clark and colleagues have shown that oral NAC attenuates
alpha-synucleinopathy and dopaminergic loss in alpha-synuclein overexpressing mice (Clark et
al., 2010). However, they did not establish the mechanism of action. Second, Berman and
colleagues have shown that NAC substantially reduced the loss of dopaminergic neurons in
EAAC1−/− mice, which have impaired neuronal cysteine uptake, reduced neuronal glutathione
content, and chronic oxidative stress (Berman et al., 2011). Third, neuroprotective effects of
NAC against dopaminergic loss have been reported in the MPTP model of Parkinson's disease
(Perry et al., 1985, Sharma et al., 2007, Pan et al., 2009). Fourth, Munoz and colleagues reported
that subcutaneous NAC robustly protects against 6-OHDA-induced dopaminergic degeneration
(Munoz et al., 2004), consistent with studies showing that NAC protects dopaminergic neurons
against 6-OHDA toxicity in vitro (Choi et al., 2008) and that NAC reduces oxidative stress in 6OHDA-treated animals (Aluf et al., 2010).

6-OHDA infusions into the striatum are known to lead to progressive dopaminergic cell death
over the course of several weeks (Sauer and Oertel, 1994). However, the Munoz study does not
address whether systemically administrated NAC will prevent nigral cell loss against 6-OHDA
toxicity at longer time-points. Another limitation of the Munoz study is that the impact of
systemic NAC on dopaminergic cells in the contralateral substantia nigra and striata was not
addressed. Furthermore, this study did not report measurements of dopaminergic neurons in
animals treated with NAC by itself (in the absence of 6-OHDA). This is an important control
group, because if NAC raises TH expression in both the absence and presence of 6-OHDA, one
cannot conclude then that it alters the impact of 6-OHDA.
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The Clark study mentioned above did not examine dopaminergic cell bodies and only reported
TH measurements in the striatum (Clark et al., 2010). We filled this gap by examining
dopaminergic cell loss at the level of the axon terminal in the striatum and the soma in the
substantia nigra to determine if the neuroprotection spanned the entire nigrostriatal pathway
(Clark et al., 2010). In addition, we examined protection of nigral cell bodies by multiple
methods to improve the rigor of our study: 1) overall expression of the dopaminergic marker TH
in the ventral mesencephalon with a low-resolution, high-sensitivity infrared Odyssey imager, 2)
counts of TH+ cell bodies in the substantia nigra by higher-resolution microscopy, and 3)
retrograde labeling of nigrostriatal proiections neurons with FluoroGold (Schmued and Fallon,
1986, Wessendorf, 1991). Furthermore, the protective effects of NAC were measured at two
separate timepoints: 10 days and 3 weeks after 6-OHDA infusions. This served to determine
whether the protective properties of NAC were long lasting or merely transient, which is
especially relevant for the treatment of chronic, progressive neurodegenerative disorders such as
Parkinson's disease. For example, the Stroke Therapy Academic Industry Roundtable (STAIR)
proposal published in 1999 recommended that investigators sacrifice animals between 2 and 3
weeks after injury (Fisher et al., 2009), as accomplished here.

The mechanism underlying NAC-mediated neuroprotection of the nigrostriatal pathway has not
been fully established. NAC can elicit neuroprotection in both glutathione-dependent and
glutathione-independent manners. For example, Clark and colleagues reported that NAC
protected striatal dopaminergic terminals with no sustained effect on glutathione levels (Clark et
al., 2010). NAC can activate NFkB and elevate Mn superoxide dismutase gene expression (Das
et al., 1995). NAC also protect cells by activation of the extracellular signal–regulated
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kinase (ERKs) cascade (Yan and Greene, 1998, Zhang et al., 2011, Sun et al., 2012). Finally,
NAC can also induce AP-1 activity by activation of ERK and the transcription factor Elk-1,
thereby leading to an increase in c-Fos expression (Meyer et al., 1993, Muller et al., 1997). The
Leak lab has shown that NAC can blunt proteotoxicity in a heat shock protein 70-dependent
manner (Jiang et al., 2013), perhaps through thiol exchanges with transcription factors such as
heat shock factor 1 that regulate transcription of Hsp70 mRNA. Another potential mechanism
whereby NAC may increase Hsp70 gene induction is by facilitating the nuclear translocation of
Nrf2 (Kwak et al., 2003, Dinkova-Kostova et al., 2004, Dinkova-Kostova, 2012). Nrf2 is
normally bound to Keap1, which has cysteine residues that nucleophiles such as NAC may
interact with in thiol exchange reactions. When Nrf2 is released from Keap2, it is no longer
degraded by the proteasome and is free to enter the nucleus and increase the transcription of
Hsp70 and related genes (Kwak et al., 2003, Dinkova-Kostova et al., 2004, Dinkova-Kostova,
2012).

In summary, beneficial effects of NAC have been reported in multiple neurological conditions
but the underlying mechanisms are poorly understood. Therefore, it is essential to establish
animal models of the therapeutic effects of NAC in order to 1) shed light on disease etiology and
2) accelerate the discovery of novel drug targets by identifying the underlying neuroprotective
mechanisms. Thus, the goal of the present study was to develop an animal model in which the
molecular mechanisms underlying the neuroprotective properties of NAC could be investigated.
Specifically, we hypothesized that NAC would protect dopaminergic cells against 6-OHDA
toxicity for at least 3 weeks and that the sustained protection would be associated with a longterm increase in Hsp70 expression in the striatum.
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Specific Aim 2: Test the hypothesis that NAC protects the somata and terminals of the
nigrostriatal pathway against 6-OHDA toxicity in vivo.

Results
NAC protects dopaminergic terminals of the nigrostriatal pathway 10 days following 6-OHDA
exposure

In the present study, NAC was injected intraperitoneally on a daily basis beginning immediately
after 6-OHDA surgeries until sacrifice 10 days later (Fig. 10). Brain sections were then
immunohistochemically stained for TH and imaged on the Odyssey imager. Ipsilateral TH levels
were divided by contralateral TH levels and expressed as a ratio, a common method of
presenting striatal TH in the literature. As expected, 6-OHDA elicited significant toxicity in
dopaminergic terminals of the ipsilateral striatum (Fig. 10A). Unexpectedly, NAC had no effect
on 6-OHDA-induced loss of ipsilateral/contralateral TH. Next, we examined the right and left
hemispheres individually. As mentioned earlier, the impact of NAC on dopaminergic neurons in
the contralateral hemisphere have not been reported in the literature. We discovered that NAC
raised TH expression in the contralateral hemisphere in 6-OHDA-treated animals (Fig. 10B).
Furthermore, there was a trend towards a NAC-mediated increase in TH levels in the ipsilateral
hemisphere in 6-OHDA-treated animals (p = 0.058, two-way ANOVA followed by Bonferroni
post hoc correction). There was no significant difference in striatal area between treatment
groups (Fig. 10C). TH signal in the striatum is sensitive to changes in striatal area, because
tracing a bigger region of interest results in a greater TH signal in proportion to the larger size of
the trace. Therefore, TH levels were expressed per unit striatal area, in order to approximate the

56

level of TH expression per dopaminergic axon terminal, i.e., the “density” of striatal TH. NAC
raised TH expression in both hemispheres in 6-OHDA-infused mice when striatal TH signal was
expressed as a function of striatal area (Fig. 10D). Consistent with previous work by Munoz et
al., our data therefore suggest that NAC can cross the blood-brain barrier and protect against 6OHDA-induced oxidative stress 10 days post-injury (Munoz et al., 2004).

Fig. 10. NAC raises TH levels in the striatum 10 days after 6-OHDA infusions. Mice were stereotaxically infused
with 4 μg 6-OHDA or an equivalent volume of vehicle (0.02% ascorbic acid in saline) into the right striatum. For
the next 10 days, mice received daily intraperitoneal injections of 100 mg/kg NAC or an equivalent volume of
phosphate-buffered saline (PBS). Forebrain sections were immunostained for the dopaminergic terminal marker
tyrosine hydroxylase (TH) and scanned on a high-sensitivity Odyssey Imager. (A) 6-OHDA significantly reduced
ipsilateral/contralateral striatal TH levels. NAC did not affect this ratio. (B) Overall TH levels in the contralateral
and ipsilateral striata. 6-OHDA reduced TH levels on the side ipsilateral to the infusion. NAC raised TH levels in
the contralateral striatum of 6-OHDA-infused animals. There was a trend towards a NAC-mediated increase in TH
levels in the ipsilateral hemisphere in 6-OHDA-treated animals (p = 0.058). (C) Striatal area was not affected by 6OHDA or NAC. (D) TH levels were expressed as a function of striatal area, a measurement that reflects average
dopaminergic terminal density (TH per unit area). NAC significantly raised TH density in both hemispheres after 6OHDA infusions. (E) Representative coronal sections through the forebrain, immunolabeled for TH+ dopaminergic
terminals and scanned on the Odyssey imager. Shown are the mean and SEM of 7–8 mice per group. *p ≤ 0.05, **p
≤ 0.01, ***p ≤ 0.001 versus 0 μg 6-OHDA; + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 ipsilateral versus contralateral; ~
p ≤ 0.05, ~~ p ≤ 0.01, ~~~ p ≤ 0.001 versus 0 mg/kg NAC; two or three- way ANOVA followed by Bonferroni post
hoc correction. Copyright 2016 by Nouraei et al. Reprinted with permission.
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NAC protects dopaminergic cell bodies of the nigrostriatal pathway 10 days following 6-OHDA
exposure

Next we investigated the neuroprotective effect of NAC in the substantia nigra by screening for
changes in the density of nigral TH labeling (Fig. 11). In contrast to the striatum, overall TH
expression in the nigra was not significantly affected by NAC treatment (Fig. 11A). Instead, 6OHDA led to a significant loss of ipsilateral nigral TH compared to the contralateral side in both
PBS and NAC-treated animals (Fig. 11A). Furthermore, there was a significant reduction in the
areas of the ipsilateral and contralateral substantia nigra by 6-OHDA in both the saline and
NAC-infused mice. This could be attributed to commissural effects of 6-OHDA (Fig. 11B).
When we expressed TH levels as a function of nigral area, 6-OHDA elicited an increase in TH
density in the contralateral nigra, a potentially compensatory effect that would not be apparent
had we only performed higher resolution dopaminergic cell counts (Fig. 11C). Next, we
expressed the ipsilateral TH signal density as a function of TH levels in the contralateral
hemisphere and found no significant toxicity by 6-OHDA in the NAC-treated animals (Fig.
11D). On the other hand, NAC did not significantly raise this measure relative to the PBS treated
animals and the preponderance of evidence collected in this study does not support long-term
protective effects of NAC in this model. Therefore, we conclude that NAC failed to protect
dopaminergic neurons in the substantia nigra from 6-OHDA toxicity 10 days post-infusion.
Blinded TH+ cell counts in the nigra also revealed no significant neuroprotective effect of NAC
(Fig. 11F).
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Fig. 11. NAC fails to protect dopaminergic neurons in the substantia nigra from 6-OHDA toxicity. Mice were
stereotaxically infused with 4 μg 6-OHDA or an equivalent volume of vehicle (0.02% ascorbic acid in saline) into
the right striatum. For the next 10 days, mice received daily intraperitoneal injections of 100 mg/kg NAC or an
equivalent volume of phosphate- buffered saline (PBS). Midbrain sections were stained for the dopaminergic
terminal marker tyrosine hydroxylase (TH). (A) Overall TH levels in the contralateral and ipsilateral nigrae. The
ipsilateral nigra had lower TH levels than the nigra contralateral to the 6-OHDA infusion site. (B) Nigral area was
significantly reduced by 6-OHDA in both hemispheres in the absence or presence of NAC. (C) TH levels were
expressed as a function of nigral area, a measurement that reflects average TH density (TH per unit area). 6-OHDA
raised TH density in the contralateral nigra and NAC did not significantly affect this measure. (D) 6-OHDA
significantly reduced ipsilateral/contralateral nigral TH levels. Although 6-OHDA did not cause a significant loss of
this measure in NAC-treated animals, NAC did not significantly increase this ratio. (E) Representative coronal
sections through the mesencephalon, immunolabeled for TH+ cell bodies and scanned on the Odyssey Imager. (F)
TH cell counts in the nigra reveal that NAC has no impact on the loss of dopaminergic cells in this structure. Shown
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are the mean and SEM of 7–8 mice per group. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 versus 0 μg 6-OHDA; + p ≤
0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 ipsilateral versus contralateral; ~ p ≤ 0.05, ~~ p ≤ 0.01, ~~~ p ≤ 0.001 versus 0
mg/kg NAC; two or three-way ANOVA followed by Bonferroni post hoc correction. Copyright 2016 by Nouraei et
al. Reprinted with permission.

NAC does not protect dopaminergic terminals of the nigrostriatal pathway three weeks following
6-OHDA exposure

The progressive neurotoxicity associated with striatal 6-OHDA infusions has been reported
previously (Sauer and Oertel, 1994). In the Munoz study, the examination of TH+ structures in
NAC-treated animals was completed only 1 week following 6-OHDA infusions (see Fig. 8 in
Munoz et al., 2004). Because the Munoz study only examined the short-term effects of NAC and
6-OHDA continues to elicit slowly progressive degeneration, we examined whether the
neuroprotective effect of NAC was long lasting. In order to address this important question, we
repeated the intraperitoneal NAC experiments in 6-OHDA infused mice and sacrificed them 3
weeks following surgeries. NAC led to no significant protection in these animals (Fig. 12A).
However, NAC reduced TH expression in the contralateral hemisphere of the animals receiving
the ascorbic acid vehicle (0 μg 6-OHDA group or third set of bars in Fig. 12A). Striatal area was
not affected by 6-OHDA or NAC at this timepoint (Fig. 12B). As a result, TH staining density
followed the same pattern as in Fig. 12A (Fig. 12C). Finally, NAC had no effect on the
ipsilateral/contralateral ratio of striatal TH expression (Fig. 12D). Thus, we conclude that
intraperitoneal NAC does not protect dopaminergic terminals of the nigrostriatal pathway against
the oxidative toxicity of 6-OHDA for the long term.
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Fig. 12. NAC fails to protect dopaminergic terminals in the striatum three weeks following 6-OHDA
infusions. Mice were stereotaxically infused with 6 μg FluoroGold (FG) into the right striatum. Seven days later,
mice were infused in the same location with 4 μg 6-OHDA or an equivalent volume of vehicle (0.02% ascorbic acid
in saline). For the next three weeks, mice received daily intraperitoneal injections of 100 mg/kg NAC or an
equivalent volume of PBS. Forebrain sections were stained for the dopaminergic terminal marker tyrosine
hydroxylase (TH) and FluoroGold (FG). (A) NAC reduced overall TH levels in the striatum contralateral to vehicle
infusion and did not protect against 6-OHDA-induced loss of TH. (B) Striatal area was not significantly affected by
NAC or 6-OHDA. (C) TH levels were expressed as a function of striatal area, reflecting TH density (TH per unit
area). NAC reduced this measure in the contralateral hemisphere of vehicle-infused animals. (D) 6-OHDA
significantly reduced ipsilateral/contralateral striatal TH levels and NAC did not impact this measure. (E)
Representative coronal sections through the forebrain, immunolabeled for TH+ terminals (green) and FluoroGold
(red). Shown are the mean and SEM of 5–8 mice per group. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 versus 0 μg 6OHDA; + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 ipsilateral versus contralateral; ~ p ≤ 0.05, ~~ p ≤ 0.01, ~~~ p ≤
0.001 versus 0 mg/kg NAC; two or three-way ANOVA followed by Bonferroni post hoc correction. Copyright 2016
by Nouraei et al. Reprinted with permission.
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NAC does not protect dopaminergic cell bodies of the nigrostriatal pathway three weeks
following 6-OHDA exposure

Next we examined the effect of NAC on dopaminergic cell bodies by screening TH and
FluoroGold signal in the ventral midbrain, as we had previously shown that these measurements
are in agreement with higher resolution cell counts. As expected from the striatal TH results, 6OHDA led to a decrease in nigral TH levels in both NAC and PBS-treated groups (Fig. 13A),
confirming that NAC did not protect nigral dopamine neurons against 6-OHDA toxicity at longer
timepoints. NAC elicited some degree of toxicity by reducing overall TH levels in all but
ipsilateral hemisphere of the control group. In this study, the area of the nigra in the ipsilateral
hemisphere was slightly increased by infusions of the vehicle ascorbic acid in both the PBS and
NAC-treated animals (Fig. 13B). The increase in the area of TH expression could be due to a
hormetic response to the mild stress induced by the acidic vehicle, and this would be abolished
by the additional stress of 6-OHDA, consistent with the J-shaped nature of hormetic doseresponse curves (Calabrese and Baldwin, 2002, Kendig et al., 2010). TH expression per unit area
was slightly reduced in the ipsilateral hemisphere of the animals treated with the ascorbic acid
vehicle, an effect that was significant in the presence of NAC (Fig. 13C). Finally, the ratio of
ipsilateral over contralateral TH expression in the substantia nigra was not altered by NAC (Fig.
13D). NAC also did not increase FluoroGold signal in the 6-OHDA infused animals (Fig. 13E).
Instead, NAC led to a reduction in FluoroGold immunoreactivity in the ascorbic acid-treated
group. This finding may suggest some toxicity induced by NAC, leading to some neuronal cell
death in the nigrostriatal pathway, which is consistent with the Odyssey imaging results in Fig.
13A.
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Given the lack of protective effects of NAC on nigral TH or FluoroGold levels after 3 weeks, we
did not proceed with dopaminergic neuronal counts or with glutathione or heat shock protein 70
measurements in this study.

We have presented the strengths and limitations of the tools used to define nigrostriatal
degeneration in Table 2.
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Fig. 13. NAC fails to protect dopaminergic neurons in the substantia nigra three weeks following 6-OHDA
infusions. Mice were stereotaxically infused with 6 μg FluoroGold (FG) into the right striatum. Seven days later,
mice were infused in the same location with 4 μg 6-OHDA or an equivalent volume of vehicle (0.02% ascorbic acid
in saline). For the next three weeks, mice received daily intraperitoneal injections of 100 mg/kg NAC or an
equivalent volume of PBS. Midbrain sections were stained for the dopaminergic terminal marker tyrosine
hydroxylase (TH) and FluoroGold (FG). (A) NAC reduced overall TH levels in the nigra in all groups except for the
vehicle-infused ipsilateral striatum. (B) Nigral area was increased by infusion of vehicle into the ipsilateral
hemisphere and 6-OHDA prevented this effect. NAC had no impact on this measure. (C) TH levels were expressed
as a function of nigral area, reflecting TH density (TH per unit area). NAC did not raise TH density in the ipsilateral
nigra. (D) 6-OHDA significantly reduced ipsilateral/contralateral nigral TH levels and NAC did not impact this
ratio. (E) Overall FluoroGold levels were reduced by 6-OHDA in the ipsilateral nigra. NAC decreased FluoroGold
levels in vehicle-infused animals. (F) Representative coronal sections through the mesencephalon, immunolabeled
for TH+ (green) and FluoroGold+ (red) cells. Shown are the mean and SEM of 5–8 mice per group. *p ≤ 0.05, **p ≤
0.01, ***p ≤ 0.001 versus 0 μg 6-OHDA; + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 ipsilateral versus contralateral; ~ p
≤ 0.05, ~~ p ≤ 0.01, ~~~ p ≤ 0.001 versus 0 mg/kg NAC; two or three-way ANOVA followed by Bonferroni post
hoc correction. Copyright 2016 by Nouraei et al. Reprinted with permission.
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Table 2: Strengths and limitations of the techniques to quantify nigrostriatal degeneration.
Copyright 2016 by Nouraei et al. 2016 Reprinted with permission.

Strengths

Limitations



Striatal and nigral TH measurements were completed on a 16-bit
imager with high sensitivity



The Odyssey imager has low resolution (21 μm)
and individual cells cannot be resolved



Blinded TH+ cell counts were performed by higher resolution
microscopy to overcome the spatial limits of the Odyssey Imager
and to complement the measurements of striatal TH



The higher resolution counts were not performed
with stereological techniques



Measurements of the area of the striatum and nigra were included



None



TH levels in the striatum and nigra were expressed per unit area
to approximate TH density and to avoid the confounding effect
of different-sized tracings of the region of interest



TH levels may be modulated by stress such that a
drop in TH density may not reflect a true loss in
dopaminergic terminals or neurons



FluoroGold was used to overcome the limitation of stress-induced
modulation of TH expression



FluoroGold exhibited some toxicity



FluoroGold can be labeled immunohistochemically so that it can
be viewed in more channels than under UV illumination and
can also be labeled more permanently with diaminobenzidine





Measurements of nigral TH levels on the Odyssey Imager were
consistent with nigral TH+ cell counts, suggesting that highthroughput Odyssey imaging can be an efficient screening tool
in models of Parkinson's disease



Loss of protein does not necessarily indicate loss of
cell numbers



Measurements of loss of FluoroGold+ structures in the nigra were
more sensitive than loss of TH+ structures



FluoroGold exhibited some toxicity



FluoroGold was infused 7d before 6-OHDA and specifically
labeled healthy projection neurons that form the nigrostriatal
pathway and project to the site of infusion



None



Neuroprotection was assessed at two different survival periods



None



We included an ascorbic acid/saline control for every 6-OHDA
group and a PBS control for every NAC group



None



We included measurements of the contralateral hemisphere as an
additional control



None



NAC was given intraperitoneally instead of orally to overcome
low oral bioavailability and potential variability from different
degrees of food intake due to the strong thiol odor of NAC



Daily intraperitoneal injections are much more
stressful than daily food intake
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None

Discussion

NAC has been investigated in many experimental models of injury and has been used in multiple
clinical trials with positive outcomes. Because of these successful experiments, there are
currently 333 ongoing clinical trials on NAC. Results from our in vitro studies demonstrate that
NAC can protect cortical neurons and neuroblastoma cells against proteasome inhibitors and
oxidative stress (Jiang et al., 2013; Posimo et al., 2013; Unnithan et al., 2012; Unnithan et al.,
2014). For example, we demonstrated that NAC can prevent cell death in response to severe,
dual hits of the proteasome inhibitor MG132 and hydrogen peroxide (Unnithan et al., 2012;
Unnithan et al., 2014). We also discovered that NAC can prevent loss of heat shock protein
defenses in neuroblastoma cells treated with high concentrations of MG132. The protective
effects of NAC were abolished in the presence of inhibitors of Hsp70 (Jiang et al., 2013). In the
present study, we gathered support for the hypothesis that NAC protects dopaminergic terminals
against 6-OHDA toxicity at short timeframes. However, we also discovered that the protective
effects of NAC wane by three weeks post-infusion. Previous studies of NAC in the 6-OHDA
model did not examine dopaminergic cell bodies at longer timeframes, did not report
contralateral values, were not blinded, and failed to include a control group with NAC alone (in
the absence of 6-OHDA). If NAC raises TH expression to equal degrees in the presence or
absence of 6-OHDA, one cannot conclude that it changes the impact of 6-OHDA. We have
observed that this issue is a common limitation of many neuroprotection studies. Therefore, we
included a saline control group for 6-OHDA, a PBS control group for FluoroGold delivery, and a
PBS control group for NAC. Both ipsilateral and contralateral values were measured. We
examined both short and long timepoints. We were blinded in all our analyses. Finally, we used
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four rigorous methods to quantify nigrostriatal cell loss to increase confidence in our
interpretations of the data.

We established that NAC raises TH expression only in the 6-OHDA group (showing that it does
change the impact of 6-OHDA), but that this effect was transient. As NAC exhibits low (~9.1%)
oral bioavailability (Olsson et al., 1988), we delivered NAC intraperitoneally at a dose of 100
mg/kg based on numerous previous studies (Munoz et al., 2004, Chakraborti et al., 2008, Bachle
et al., 2011, Smaga et al., 2012, Comparsi et al., 2014, Gunay et al., 2014, Jaccob, 2015, Prakash
et al., 2015, Soleimani Asl et al., 2015, Truini et al., 2015). Furthermore, The World Health
Organization guidelines for NAC administration in acetaminophen overdose are 150 mg/kg
intravenously over 1 h, followed by 50 mg/kg intravenously over 4 h, and 100 mg/kg
intravenously over 16 h (Pauley et al., 2015). NAC has been delivered intravenously at doses as
high as 150 mg/kg in clinical trials on Parkinson's patients (Holmay et al., 2013). NAC was
delivered intravenously at 100 mg/kg daily for 21 days in patients undergoing
hematopoietic stem cell transplantation (Ataei et al., 2015). In patients with myocardial
infarction, NAC was delivered via the intracoronary route at 100 mg/kg (Eshraghi et al., 2016).
In order to prevent oral mucositis in patients who receive high-dose chemotherapy, NAC was
delivered intravenously at 100 mg/kg per day for at least 2 weeks (Moslehi et al., 2014). Thus,
our 100 mg/kg dose is in accordance with the clinical literature. However, our data suggest that
100 mg/kg intraperitoneal NAC can lead to mild nigrostriatal degeneration on its own—even in
the absence of 6-OHDA—raising significant concerns about its long-term use in humans. Other
authors have similarly argued that NAC may have toxic properties after chronic treatments
(Munoz et al., 2004, Zaeri and Emamghoreishi, 2015). Thus, in future studies, we aim to deliver
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NAC orally at lower doses, either in food or water. Daily intraperitoneal injections may be much
more stressful than food intake even if NAC has an unpleasant, strong thiol odor that makes it
less palatable. Preliminary data in the Leak lab show that the addition of NAC does not change
food intake rates in mice (Mason and Leak, unpublished).

The lack of sustained neuroprotective effects of NAC in the present study has important
implications for the long-term clinical use of NAC, which would be necessary in patients with
progressive neurodegenerative disorders such as Parkinson's disease. Although clinical trials of
NAC in Parkinson’s patients led to positive outcomes, the effect sizes were relatively small
(Monti et al., 2016). One possibility is that mild toxicity of NAC, as shown by the present work,
reduced the sizes of the protective effects. However, in the Monti et al study, NAC was delivered
intravenously at a dose of 50 mg/kg once a week and orally at 1200 mg/person on a daily basis.
Thus, we delivered a higher daily dose of NAC than in the Monti study, as our dose was based
on earlier animal and human studies that had employed the 100 mg/kg dose or higher (Munoz et
al., 2004, Chakraborti et al., 2008, Bachle et al., 2011, Smaga et al., 2012, Holmay et al., 2013,
Comparsi et al., 2014, Gunay et al., 2014, Moslehi et al., 2014, Ataei et al., 2015, Jaccob, 2015,
Pauley et al., 2015, Prakash et al., 2015, Soleimani Asl et al., 2015, Truini et al., 2015, Eshraghi
et al., 2016).

It is worth noting in this context that NAC mediated long-term protection of striatal TH in alphasynuclein overexpressing mice in the Clark study (Clark et al., 2010). Clark and colleagues
further showed that the NAC-mediated increase in nigral glutathione was no longer apparent at
the time of the striatal neuroprotection assay. In the present study, there may also be only

68

transient upregulation of glutathione with dietary NAC, as in the Clark study, although further
studies would be necessary to confirm this. This could explain why the protection of
dopaminergic terminals was not sustained. Glutathione is known to inhibit glutathione synthetase
by a negative feedback loop, thereby limiting its own production (Lushchak, 2012) Glutathione
would be expected to reduce oxidative injury in the 6-OHDA model, but have less impact on
proteinopathic stress. Therefore, we hypothesized that an upregulation of Hsp70 by NAC might
underlie the protective effects of NAC in multiple in vitro models of proteotoxic cell death (Jiang
et al., 2013; Posimo et al., 2013; Unnithan et al., 2012; Unnithan et al., 2014). Hsp70 has been
shown to protect cells against both oxidative and proteotoxic stress (Jiang et al., 2013; Posimo et
al., 2013; Unnithan et al., 2012; Unnithan et al., 2014). It is possible that there was no
upregulation of Hsp70 in vivo in the present study or that the upregulation of Hsp70 in vivo was
transient. Hsp70 is also known to inhibit its own production in a negative feedback loop with
HSF1 (Zorzi and Bonvini, 2011, Vjestica et al., 2013).

In the present study, NAC only increased TH expression in the 6-OHDA-treated animals at early
timepoints. That is, there was no basal effect of NAC delivered on its own (in the absence of 6OHDA). One possible explanation for this specificity is that 6-OHDA reduces the levels of
reduced glutathione and increases the levels of oxidized glutathione. This would release
glutamate-cysteine ligase from feedback inhibition and thereby allow NAC to provide the ratelimiting precursor (cysteine redisue) for additional glutathione synthesis, at least at early
timpoints, but only in the 6-OHDA group.

In our in vivo studies, we used multiple rigorous methods to quantify nigrostriatal degeneration
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and validated the tools. First, we used an Odyssey imager to measure loss of TH protein in the
striatum and expressed the data in multiple ways to ensure that changes in striatal area did not
confound our interpretations. Next, changes in dopaminergic neurons in the substantia nigra were
measured by four techniques: 1) measurements of TH expression levels and nigral area using the
Odyssey Imager and 2) dopaminergic cell counts using a higher resolution microscopy, 3)
measurements of FluoroGold levels using the Odyssey imager, and 4) counts of individual
FluoroGold+ nigral neurons. Many studies in the 6-OHDA model report TH or dopamine values
only as an ipsilateral/contralateral ratio without reporting the contralateral values. As explained
in the classic stereology literature, expressing data as a ratio is subject to the “reference trap”
(Braendgaard and Gundersen, 1986, Hyde et al., 2007). Thus, one cannot determine from a ratio
whether the changes are attributable to the numerator or the denominator, or both. The
investigator is usually inclined to assume that the ratio reflects the numerator and not the
denominator because the latter is the reference value. Our results clearly show that contralateral
TH levels can change in response to the treatments to the same degree as ipsilateral TH levels
(Fig. 10). Therefore, the most appropriate control for this type of study of the basal ganglia is the
ipsilateral hemisphere in the vehicle-treated animals. As we expected, it was important to
examine the therapeutic potential of NAC at multiple timepoints, to report contralateral values,
and to examine the cell bodies in addition to the terminals.

We have included a list of the strengths and limitations of the techniques used here to assess
nigrostriatal degeneration (Table 2). Here, we will only highlight some of the major points
mentioned in Table 2 to avoid repetition. We found that FluoroGold is a highly sensitive tool to
quantify nigrostriatal degeneration. Because it is such a robust tract-tracer, it has been employed
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in many studies (Sauer and Oertel, 1994, Mandel et al., 1997, Choi-Lundberg et al., 1998,
Yamada et al., 1999, Kozlowski et al., 2000, Aymerich et al., 2006, Ebert et al., 2008, Anastasia
et al., 2009, Cohen et al., 2011). Consistent with one study showing that FluoroGold may be
toxic (Naumann et al., 2000), we found that FluoroGold slightly reduces nigral area (see Fig.
9B). Therefore, it might be worth examining more inert tract-tracers, such as biotinylated dextran
amines. However, the dextran amines are transported in both retrograde and anterograde
directions. This would preclude using the Odyssey imager to measure overall tracer levels in the
nigra as a specific measure of the nigrostriatal efferent pathway. Another option would be the
retrograde tracer True Blue. Although it fades quickly, this tracer has been reported to be less
toxic than FluoroGold over long survival timeframes (Garrett et al., 1991).

One of the limitations of using the Odyssey imager to screen overall TH levels is that loss of
protein expression may not necessarily represent loss of axon terminals or soma numbers. For
example, in response to stress, neurons may retract their dendrites or lose TH expression without
any degeneration. Thus, it is important to include dopaminergic cell counts to accompany
measurements of striatal and nigral TH. Nevertheless, the degree of overall loss of nigral TH
expression according to the infrared imager was consistent with the degree of loss of TH+ cell
counts. Thus, the Odyssey imager is useful as a rapid screening tool prior to more lowthroughput measurements and the two types of measurements should be viewed as
complementary. For example, increases in TH expression per unit area, as detected by the
Odyssey imager, may suggest that individual nigral cells are producing more TH if there is no
parallel change in cell numbers. Another advantage of using the Odyssey imager is that nigral
and striatal areas are easily measured, loss of which can also reveal some form of toxicity. In the
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present study we did not use stereological techniques for cell counts. However, we counted all
TH+ neurons in three enormous stitched microscopic images at mid levels of the nigra. Nonstereological counting techniques are subject to over or under-reporting cell numbers. However,
such errors would be expected to occur at same rates for both the experimental and control
groups in the present study.

As with stereological studies of dopamine neurons, TH cell counts in the present report are
highly dependent on TH expression levels. For example, it is possible that dopamine cells of the
nigrostriatal pathway may express TH at levels too low to be detected by immunohistochemistry
and would therefore not be counted even by stereological techniques. To address this problem,
previous studies have reported cell counts of Cresyl Violet-stained nigral cells. However, Nissl
substance is also expressed in glial cells and glial cells can undergo hyperplasia in response to
stress, which would result in higher nigral cell counts with the Cresyl Violet technique. To
circumvent this issue, we employed FluoroGold to specifically label dopamine neurons of the
nigrostriatal pathway. Another alternative would be to use a neuronal marker such as NeuN.
However, NeuN is not a reliable marker of dopamine neurons in the substantia nigra, as it is not
even present in some TH-expressing dopamine neurons (Cannon and Greenamyre, 2009)
Additionally, neuronal markers such as NeuN would not specifically label the efferent projection
neurons of the nigrostriatal pathway, the loss of which is an important variable for modeling
Parkinson's disease.

In summary, we used multiple independent measurements of nigrostriatal degeneration to
rigorously study the therapeutic potential of NAC. NAC offered transient protection in our
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model, but the protective effects were diminished at longer timepoints. The strengths and
limitations of using an established retrograde tracer to quantify nigrostriatal degeneration have
been described in detail. Alternatives for future studies, such as delivering NAC by food or water
and switching to less toxic tracers have been proposed. Finally, chronic treatment with NAC may
even exert toxic effects of its own. This has important implications for clinical trials of NAC in
patients with Parkinson's disease, a severe, progressive, neurodegenerative disorder that would
demand long-term treatment strategies.
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Chapter 3
Rationale

Progressive cognitive decline is evident in many patients in mid-to-late stage Parkinson disease
(Braak et al., 2003, (Lue et al., 2016). Indeed, Parkinson’s patients have a 4-6 fold greater
incidence of dementia compared to healthy individuals (Hobson and Meara, 2004, MetzlerBaddeley, 2007). Clinical studies following patients with Parkinson’s disease for 8 or 20 years
found cumulative cognitive deficit prevalence rates of 78% and 83%, respectively (Aarsland et
al., 2003, Hely et al., 2008). A combination of motor dysfunction and cognitive dementia
increase mortality 3-8 fold and greatly impact quality of life (Xu et al., 2014).

In Parkinson’s disease, motor symptoms typically occur prior to the onset of cognitive
impairments (Aarsland, 2016). The hippocampus develops Lewy pathology in Braak stages III
and IV (Braak et al., 2003a). Stages V and VI are associated with the formation of alphasynuclein inclusions in the neocortex. Alpha-synucleinopathy in the hippocampus and neocortex
are strongly correlated with cognitive deficits in Parkinson’s disease (Kalaitzakis and Pearce,
2009). A similar topographical pattern has been reported in Lewy body dementia, a condition
where symptoms of cognitive impairment appear before movement deficits. To date, there are
few models of Parkinson’s disease dementia and of Lewy pathology in the hippocampus.
Furthermore, current treatments for cognitive deficits in Parkinson’s disease are not very
effective and are largely limited to cholinesterase inhibitors and Memantine, a partial NMDAantagonist (Aisen et al., 2012). It is essential to diagnose cognitive deficits at early stages in
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order to improve the effectiveness of the limited treatment options (Caviness et al., 2011).
Therefore, there is an urgent need for agents to improve cognitive function and/or to delay the
rate of cognitive decline in Parkinson’s disease dementia and Lewy body dementia.

Dehydroepiandrosterone (DHEA) and its sulfated ester DHEAS are two of the most abundant
neurosteroids synthesized within the nervous system (Flood et al., 1988, Migues et al., 2002).
Some studies suggested that the levels of DHEAS are significantly reduced in the brains of
patients with Alzheimer’s disease compared with the healthy individuals (Nasman et al., 1991,
Leblhuber et al., 1993, Solerte et al., 1999, Murialdo et al., 2000). However, the link between
reduced levels of DHEAS and neurodegenerative diseases is still controversial. In vivo studies in
rats indicate that intraperitoneal injections of DHEAS enhance hippocampal acetylcholine
release, as measured by in vivo microdialysis (Rhodes et al., 1996). Consistent with these
findings, our lab showed that DHEAS improved memory function in rats with a selective
cholinergic lesion of the septohippocampal tract (data unpublished). Furthermore, inhibition of
the steroid sulfatase enzyme, which increases DHEAS levels by preventing its conversion back
to DHEA, can facilitate the memory-enhancing effects of DHEAS (Johnson et al., 1997, Li et al.,
1997, Johnson et al., 2000). Other studies have also demonstrated that DHEAS protects
hippocampal neurons against glutamate-induced neurotoxicity in the hippocampus while little
protection is obtained from the equivalent doses of DHEA (Mao and Barger, 1998). These
results suggest that DHEAS is a neuroprotective agent with the potential to alleviate dementia
associated with Parkinson’s disease or related neurodegenerative disorders. Therefore, we
hypothesized that DHEAS may improve memory function in rats infused with alpha-synuclein
fibrils into the hippocampus and/or striatum, a model of Parkinson’s disease dementia.
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Specific Aim 3: Test the hypothesis that DHEAS will improve memory function in an alphasynuclein model of Parkinson’s disease dementia.

Results – Preliminary Study
Hippocampal and/or striatal injection of alpha-synuclein fibrils impaired novel place and novel
object recognition respectively in rats (preliminary data)

Male Sprague Dawley rats (3 months old) were bilaterally infused with alpha-synuclein fibrils
into the hippocampus and/or striatum. Seven months later the animals were tested for declarative
memory using novel object (NOR) and novel place (NPR) recognition paradigms. Pilot results
demonstrate significant impairments in novel object recognition (Fig. 14) but not novel place
recognition in animals injected in the dorsal striatum with alpha-synuclein (P<0.01) and a trend
toward impairment in novel place recognition but not object recognition in rats injected in the
hippocampus (P=0.06) (Fig. 14).
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Fig.14. Novel object and novel place recognition test at seven months. Rats were infused with alpha-synuclein
fibrils into the hippocampus and/or striatum bilaterally. Seven months later the animals were tested for declarative
memory using novel object and novel place recognition paradigms. (A) Novel object recognition but not novel place
recognition was significantly impaired in animals injected in the dorsal striatum with alpha-synuclein (P<0.01). (B)
There was a trend toward impairment of novel place recognition but not object recognition in rats injected in the
hippocampus (P=0.06). *p ≤ 0.05 versus control, n=3-4 rats per group.

Alpha-synuclein fibrils led to mild loss of NeuN in the hippocampus (preliminary data)

Animals were then perfused and brains were immunostained for the neuronal marker NeuN.
Sections were imaged on an Odyssey Infrared Imager and quantified in blinded fashion.
Histological examination of hippocampi injected with alpha-synuclein fibrils revealed a
significant loss of NeuN signal in the hippocampus by seven months after infusion (P<0.01)
(Fig. 15). These preliminary results suggest that specific cognitive impairments in Parkinson’s
disease may be related to loss of NeuN signal associated with alpha-synucleinopathy in cortical
and subcortical structures.
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Fig.15. Alpha-synuclein fibrils elicit NeuN loss in the rat hippocampus at seven months. Rats were infused with
alpha-synuclein fibrils into the hippocampus and/or striatum bilaterally. Seven months later the animals were
perfused and brains were immunostained for the neuronal marker NeuN. **p ≤ 0.01 versus control, n=3-4 rats per
group.

Alpha synuclein infusions had no effect on memory function or NeuN signal
As the preliminary results were promising, more animals were injected with alpha-synuclein
fibrils or PBS into the hippocampus and/or striatum bilaterally. Six to seven months postsurgery, we injected DHEAS (10 mg/kg) intraperitoneally immediately before the novel
object/place recognition tests to investigate whether memory functions would be improved.
Neither alpha-synuclein infusions nor DHEAS injections led to significant effects on NOR or
NPR in this study (Fig. 16). Subsequent immunohistochemical analyses revealed only sparse
accumulations of pSer129+ inclusions (Fig.17) and no significant changes in the dopaminergic
marker TH in the striatum or the neuronal marker NeuN in the striatum or hippocampus (Fig.18
A-F), due to technical limitations such as improper sonication parameters and application of low
doses of fibrils.
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Fig.16. Novel object and novel place recognition test at seven months. Rats were infused with alpha-synuclein
fibrils into the hippocampus and/or striatum bilaterally. Seven months later the animals were tested for declarative
memory using novel object (NOR) and novel place (NPR) recognition paradigms. (A) Neither alpha-synuclein
infusions nor DHEAS injections had significant effects on NOR. (B) Neither alpha-synuclein infusions nor DHEAS
injections had significant effects on NPR in this study, n=8 rats per group.
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Fig. 17. Alpha-synuclein fibrils led to only mild alpha-synuclein pathology in dentate gyrus and CA1. Rats were
infused with alpha-synuclein fibrils into the hippocampus and/or striatum bilaterally. Seven months later the animals
were perfused and brains were immunolabeled for pathologically phosphorylated alpha-synuclein (pSer129) Alphasynuclein fibrils led to only mild alpha-synuclein pathology in the dentate gyrus and CA1.
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Discussion

First, we injected alpha-synuclein fibrils bilaterally into the rat hippocampus and/or striatum to
elicit protein-misfolding stress, the major hallmark of all neurodegenerative disorders. The novel
object recognition and novel object place recognition tests were employed after 7 months. In a
pilot study, mice injected with alpha-synuclein fibrils exhibited significant loss of memory
compared to PBS-treated controls. Alpha-synuclein injections in the striatum led to loss of novel
object recognition skills whereas injections in the hippocampus impaired novel place
recognition. Next, we injected DHEAS intraperitoneally immediately before the novel
object/place recognition tests to investigate whether memory functions would be improved.
Neither alpha-synuclein infusions nor DHEAS injections exerted significant effects on novel
object/place recognition tests in this study. Immunohistochemical analyses suggested only mild
alpha-synuclein pathology and no significant changes in levels of the dopaminergic marker TH
or the neuronal marker NeuN in the striatum or hippocampus.

Although the preliminary data were promising, there can be differences in the concentrations of
the fibrils from batch to batch or even within the same batch, as the fibrils may settle to the
bottom of the tube quickly during the aliquoting procedure. At the time of this study, the Leak
lab had not yet optimized the parameters of sonication. Fibril sonication parameters are
important in the formation and transmission of Lewy-like pathology (Volpicelli-Daley et al.,
2014). Furthermore, in the present study, we used lower doses of fibrils (2 μg per site injection)
compared to the 5 μg per site injection that was reported previously (Luk et al., 2012a), as we
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had limited access to fibrils in this study. All of these technical limitations may explain our
negative results.
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Chapter 4
Rationale

The classical neuropathological feature of Lewy body disorders is the accumulation of the
synaptic protein alpha-synuclein in fibrillar aggregates (Wakabayashi et al., 2007). Lewy
pathology commences in the olfactory bulb and medulla oblongata and is known to reach the
basal forebrain and mesocortex in Braak stage IV (Braak et al., 2003a). This appearance of Lewy
pathology in the telencephalon is correlated with the emergence of cognitive impairments or
dementia. Dementia is a common nonmotor symptom in Parkinson’s disease, with a prevalence
of ~50% (Kalaitzakis and Pearce, 2009). Furthermore, 24-36% of patients with newly diagnosed
Parkinson’s disease exhibit some form of memory deficits (Foltynie et al., 2004, Muslimovic et
al., 2005, Kalaitzakis and Pearce, 2009). Parkinson's disease patients with dementia exhibit
neuronal loss in several brain regions, including the locus coeruleus, nucleus basalis of Meynert,
dorsal raphe, ventral tegmental area, and the medial substantia nigra (Kalaitzakis and Pearce,
2009). There is a correlation between the severity of clinical dementia and the number of Lewy
bodies in the entorhinal cortex and the density of Lewy neurites in hippocampal CA2 (NaganoSaito et al., 2005). Alpha-synucleinopathy reaches CA2 of the hippocampus in Braak stages IIIIV (Parkkinen et al., 2008). Magnetic resonance imaging (MRI) studies have shown that
hippocampal atrophy is associated with cognitive deficits in nondemented Parkinson’s disease
patients (Nagano-Saito et al., 2005). Dementia with Lewy bodies, a condition distinct from
Parkinson’s disease dementia, is also known to be associated with dense alpha-synucleinopathy
in CA2 of the hippocampus (Del Ser et al., 2001). The distinction between dementia with Lewy
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bodies and Parkinson’s disease dementia is based on the temporal sequence of cognitive versus
motor symptoms (Mrak and Griffin, 2007). If motor symptoms appear prior to dementia by more
than one year, the patient is diagnosed with Parkinson’s disease dementia. However, when
dementia appears within 12 months of motor symptoms, a diagnosis of dementia with Lewy
bodies should be considered.

The importance of the hippocampus in memory and learning is well established by many animal
and clinical studies. For example, long-term potentiation in synaptic function has been well
studied in the hippocampus (Bliss and Collingridge, 1993). It is therefore not surprising that
many studies report a correlation between Lewy neurite density in CA2 and cognitive
impairments (Churchyard and Lees, 1997, Pagani et al., 2005, Kalaitzakis et al., 2009). However,
there are few available models of hippocampal alpha-synucleinopathy with which to mimic the
memory deficits seen in Parkinson’s disease dementia and dementia with Lewy bodies.

For the last 40 years, the majority of research in Parkinson’s disease was limited to motor
symptoms, which are generally attributed to the loss of dopaminergic neurons (Alexander, 2004).
Recently, the importance of non-motor parkinsonian symptoms has become increasingly evident
and animal models have been developed that exhibit some, but not all, of the non-motor features
of this condition. For example, many different transgenic lines of mice over-expressing alphasynuclein have been generated (Fleming and Chesselet, 2006, Lim et al., 2011, Paumier et al.,
2013). Lim and colleagues showed that the impairments in contextual fear memory in mice overexpressing alpha-synuclein at 8 months is correlated with accumulation of abnormal alphasynuclein in limbic areas, especially in the hippocampus (Lim et al., 2011). Other groups
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demonstrated that mice overexpressing human A53T mutant alpha-synuclein develop fine
sensorimotor and synaptic impairments before the onset of late-stage gross motor and memory
deficits related to Parkinson’s disease (Paumier et al., 2013). The A53T transgenic mice exhibit
spatial memory deficits at 6 and 12 months, as measured by Y-maze cognitive testing. One
important limitation of this model is that behavioral impairments do not seem to progress with
time, but rather develop in an all or none fashion with extensive variability across animals. The
early-onset deficits also do not correlate with the accumulation of alpha-synuclein, suggestive of
additional mechanisms responsible for early symptoms. In sum, this transgenic model shows fine
sensorimotor and synaptic dysfunction long before alpha-synuclein accumulation or obvious
motor symptoms become evident. The transgenic models cannot be used to answer whether
hippocampal Lewy pathology is responsible for cognitive deficits, as gene expression is
increased in neurons throughout the brain. Human studies can also not address whether the link
between hippocampal Lewy pathology and cognitive dysfunction is causal or merely correlative.

All of the transgenic animal models are based on the genetics of familial Parkinson’s disease.
However, most cases of Parkinson’s disease are sporadic in nature, in that only 10–15% of
patients have a positive family history of the condition (Papapetropoulos et al., 2007). Therefore,
another concern with employing transgenic models is the relevance of the pathophysiological
mechanisms triggered by rare mutations to the non-familial sporadic cases. Recently, researchers
have infused recombinant alpha-synuclein fibrils into CA1/CA2 of the hippocampus and the
striatum (Luk et al., 2012a, Sacino et al., 2013). However, as mentioned above, hippocampal
Lewy pathology in Parkinson’s disease is centered in CA2/3 (Del Ser et al., 2001). Luk and
colleagues did not report any memory deficits following hippocampal injection of fibrils, as
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assessed using the Y maze (Luk et al., 2012a). Sacino et al. failed to measure cognitive functions
after hippocampal fibril injections, and reported severely limited spread of alphasynucleinopathy from the injection site (Luk et al., 2012a, Sacino et al., 2013). Furthermore,
none of these previous studies involved bilateral injections, even though it is possible that the
unlesioned hemisphere may compensate against unilateral injuries. Therefore, the first goal of
this aim is to develop a model of bilateral hippocampal alpha-synucleinopathy with greater
potential for behavioral impairments and that could be used to test therapies aimed at
ameliorating cognitive deficits in Parkinson’s disease dementia or dementia with Lewy bodies.
In order to accomplish this goal, two month-old CD1 mice were bilaterally infused with alphasynuclein fibrils (5 μg) or PBS into CA2/3 of hippocampus. We measured behavioral
impairments at 2 and 3 months post-infusion. As mentioned above, although hippocampal alphasynucleinopathy is known to be correlated with cognitive deficits in Lewy body disorders
(Churchyard and Lees, 1997, Pagani et al., 2005, Kalaitzakis et al., 2009), it is not known if this
link is causal or correlative. If the link is indeed causal, this would significantly influence drug
development by providing a clinically relevant model of parkinsonian dementia. Therefore, we
also aimed to investigate whether hippocampal alpha-synucleinopathy following bilateral
infusions of fibrils leads to the emergence of memory deficits as in Parkinson’s disease dementia
or dementia with Lewy bodies.

Alpha-synuclein is thought to be endocytosed into endosomes and degraded via autophagy or
proteasomal degradation systems (Luk et al., 2009, Volpicelli-Daley et al., 2011). However,
fibrillar structures may poke holes in vesicular membranes such as lysosomes and endosomes
and then have access to the cytosol, where misfolded and fibrillar alpha-synuclein may act as a
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template to seed similar misfolding in native, endogenous alpha-synuclein molecules that are
nearby. This fibrillar template may therefore seed pathology that is self- gating and spreads
throughout the central nervous system via synaptic contacts over time (Glabe and Kayed, 2006,
Goedert et al., 2010). Indeed, several investigators have hypothesized that the pattern of
transmission of Lewy pathology following fibril injections is based on established
neuroanatomical connections, even though the transmission through neuroanatomical circuits has
not been investigated rigorously (Luk et al., 2012a, Sacino et al., 2013). Therefore, we assessed
the pattern of spread of alpha-synucleinopathy after fibril infusions into CA2/CA3 and compared
that to the literature on hippocampal afferents and efferents.

According to the tract-tracing literature, major afferents of the hippocampal formation arise in
the medial septum, diagonal band of Broca, and entorhinal cortex (Segal, 1977, Swanson and
Cowan, 1977, Swanson, 1982, Vertes, 1992, Conde et al., 1995, Yoshida and Oka, 1995,
Gasbarri et al., 1997, Risold and Swanson, 1997, Acsady et al., 1998, Naber and Witter, 1998,
McKenna and Vertes, 2001, O'Mara et al., 2001, Francisco E. Olucha-Bordonau, 2015, Natalie
L.M. Cappaert, 2015, Paxinos, 2015). More minor projections arise in the supramammillary
nucleus and the monoaminergic cell groups in the locus coeruleus and raphe (Segal, 1977,
Swanson and Cowan, 1977, Swanson, 1982, Vertes, 1992, Conde et al., 1995, Yoshida and Oka,
1995, Gasbarri et al., 1997, Risold and Swanson, 1997, Acsady et al., 1998, Naber and Witter,
1998, McKenna and Vertes, 2001, O'Mara et al., 2001, Francisco E. Olucha-Bordonau, 2015,
Natalie L.M. Cappaert, 2015, Paxinos, 2015). Septal projections terminate in all fields of the
hippocampal formation but are particularly prominent in the dentate gyrus (Swanson and Cowan,
1977). The septal projection to CA3 originates mainly in the medial septal nucleus and nucleus
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of the horizontal diagonal band of Broca, similar to the septal projections to the dentate gyrus
(Yoshida and Oka, 1995). Cells in the medial septum and the dentate gyrus both receive
collaterals from the same cells in the medial raphe nucleus (McKenna and Vertes, 2001). The
dentate gyrus also receives a minor and diffusely distributed projection from cells located in the
ventral tegmental area (Swanson, 1982, Gasbarri et al., 1997). As mentioned above, a
hypothalamic projection to the dentate gyrus arises from supramammillary area (Segal, 1977,
Vertes, 1992).

There are several reports of amygdalar projections into the hippocampus (Pikkarainen et al.,
1999, Cenquizca and Swanson, 2007). The amygdaloid complex projects to the hippocampus
and parahippocampal areas, including to the subiculum (Pikkarainen et al., 1999). The
basolateral division of amygdala targets the stratum oriens and stratum radiatum of CA3 and
CA1 as well as the subiculum. The basomedial division of the amygdala projects to the stratum
lacunosum-moleculare of CA1 (Pikkarainen et al., 1999). The amygdala also receives significant
reciprocal projections from the hippocampal formation (ventral regions of field CA1) and
prefrontal cortex (Cenquizca and Swanson, 2007).

Swanson and colleagues have shown that most of the hippocampal efferent projections originate
from the subiculum (Swanson and Cowan, 1977), and that the only subcortical projection from
CA3 terminates in the lateral septal nucleus. The pattern of the projections from CA3 to the
lateral septum differs from that of CA1 projections, as CA3 preferentially projects to more
caudal levels of the lateral septum (Risold and Swanson, 1997). The major projections arising
from CA1 pyramidal cells descend into the stratum oriens or the alveus and then extend towards
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the subiculum (Finch and Babb, 1981, Finch et al., 1983, Amaral et al., 1991). The projections of
the subiculum target a number of cortical and subcortical regions, including medial portions of
the anterior olfactory nucleus and the agranular insular cortex (Conde et al., 1995, Naber and
Witter, 1998, O'Mara et al., 2001). In addition, the ventral CA1/subiculum region of the
hippocampus provides prominent inputs to medium spiny neurons of the nucleus accumbens
(Floresco et al., 2001).

Hippocampal commissural projections arise mainly from mossy cells in the hilar region of the
dentate gyrus and from CA3 pyramidal cells (Swanson et al., 1980, Zappone and Sloviter, 2001).
Injections of the retrograde tracer FluoroGold that are centered in the dentate gyrus of the medial
hippocampus elicit contralateral retrograde labeling exclusively in dentate hilar neurons, whereas
larger injections spanning CA3 and CA1 (and the dentate gyrus) lead to contralateral labeling in
CA3 as well as the hilum (Zappone and Sloviter, 2001). The existence of specific axonal
pathways connecting the two hippocampi allows us to examine the spread of Lewy-like
pathology across commissural circuits. Therefore, in addition to the bilateral infusions of fibrils
into CA2/CA3, we also infused fibrils unilaterally in order to study the topographical pattern of
inclusion formation within commissural and associational circuits. Understanding the
mechanisms of propagation and transmission of the Lewy-like pathology could lead to the design
of novel therapeutic interventions in Parkinson’s disease and other alpha-synucleionopathies.

Specific Aim 4: Determine if Lewy-like pathology in CA2/CA3 will lead to cognitive deficits in
an experimental model of Parkinson’s disease dementia or dementia with Lewy bodies.
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Results
Unilateral injections of alpha-synuclein fibrils into CA2/3 lead to the formation of dense
pSer129+ inclusions in the hippocampus and entorhinal cortex

Fibril sonication parameters are important in the formation and transmission of the pathology
(Volpicelli-Daley et al., 2014). We have recently conducted an animal study to optimize the
fibril sonication protocol and discovered that 1h sonication renders the alpha-synuclein model
more aggressive and robust (Mason et al., 2016). In that study, we showed that infusions of 1
hour-sonicated fibrils into the OB/AON led to transmission of alpha-synucleinopathy from
olfactory structures deep into the limbic rhinencephalon, including all major afferent brain
regions—such as the piriform and entorhinal cortices, amygdala, and hippocampus. Thus, we
used these validated sonication parameters to investigate whether infusions of 1 hour waterbathsonicated alpha-synuclein fibrils into hippocampal CA2/3 lead to the formation of Lewy-like
pathology in the hippocampus and transmission through neuroanatomical circuits such as the
perforant and septohippocampal pathways. Animals were sacrificed three months post-infusion
and brains were immunolabeled for pSer129, the pathologically phosphorylated form of alphasynuclein (Sato et al., 2013). Nuclei were labeled with the DRAQ5 or Hoechst nuclear stains.
These mice developed robust alpha-synucleinopathy in the hippocampus and at some, but not all
the afferent sites that send first-order projections to the hippocampus, such as the amygdala,
entorhinal cortex, and lateral septum (Figure 19) (Segal, 1977, Swanson and Cowan, 1977,
Swanson, 1982, Vertes, 1992, Conde et al., 1995, Yoshida and Oka, 1995, Gasbarri et al., 1997,
Risold and Swanson, 1997, Acsady et al., 1998, Naber and Witter, 1998, McKenna and Vertes,
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2001, O'Mara et al., 2001, Francisco E. Olucha-Bordonau, 2015, Natalie L.M. Cappaert, 2015,
Paxinos, 2015). Fibril infusions centered in CA2/3 led to dense Lewy-like pathology in cornu
ammonis and the dentate gyrus of the hippocampal formation and layer II of the entorhinal
cortex, demonstrating successful transmission of alpha-synucleinopathy through the perforant
path, consistent with previous work (Sacino et al., 2014a). Additional Lewy-like pathology was
detected in the ectorhinal/perirhinal cortex, which projects into the hippocampus and is an
important gateway for the spread of Lewy pathology from the mesocortex into neocortex in
Braak stages V and VI (Braak et al., 2003a, Braak et al., 2003b). Extrahippocampal pSer129+
inclusions were also found in the lateral septum (dorsal and ventral divisions) and amygdaloid
complex (central, cortical, and basal nuclei). PBS injections did not result in any alphasynucleinopathy (Figure 19).
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Fig. 19. Transmission of alpha-synucleinopathy after infusions of waterbath-sonicated fibrils into
CA2/3 of the hippocampus. Two month-old mice were unilaterally infused with alpha-synuclein fibrils (5
μg) or an equal volume of phosphate-buffered saline (PBS) into CA2/CA3. Fibrils were sonicated for 1 h
in a waterbath prior to infusion. Three months later, coronal brain sections were collected. (A) Shown are
images of pSer129 and Hoechst staining in the hippocampus and entorhinal cortex in PBS and fibrilinfused animals. (B-D) The pathology was transmitted into extrahippocampal regions such as the
ectorhinal cortex, amygdala, accumbens, and lateral septum. All groups were stained in parallel and
captured at the same exposure and intensity scaling. All abbreviations are listed in Table 5.
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Most perinuclear pSer129+ inclusions are formed within cells expressing the neuronal nuclear
marker NeuN

Next we characterized the nature of the inclusions formed three months following fibril
injections into CA2/3. We confirmed that most perinuclear inclusions were wrapped around
NeuN+ nuclei (Figure 20A). This was verified with confocal microscopy (Figure 20B). The
morphology of these inclusions is similar to that exhibited by some Lewy bodies in mouse and
human tissue (Osterberg et al., 2015).

A

B

Fig. 20. The development of dense perinuclear and neuritic inclusions following fibril infusions. (A)
Two month-old mice were unilaterally infused with 1 h waterbath-sonicated alpha-synuclein fibrils (5 μg)
or an equal volume of phosphate-buffered saline (PBS) into the CA2/3 of hippocampus. Three months
later, sagittal brain sections were collected and stained with antibodies against pSer129 and the neuronal
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nuclear marker NeuN. Hoechst-labeled nuclei are shown in blue. The pSer129+ inclusions were
perinuclear or found in processes. Arrows point to pSer129+ somal inclusions and arrowheads to neuritic
inclusions. (B) Confocal microscopy confirmed the perinuclear localization of pSer129+ structures.

Preadsorption of pSer129 antibodies with pSer129 blocking peptides lead to loss of
immunoreactivity

To confirm the specificity of the primary antibody raised against phosphorylated alphasynuclein, we performed two sets of control experiments. First, we preadsorbed the primary
antibody with 10-fold excess pSer129 blocking peptide. Sections were then exposed to free or
antigen-bound primary antibodies. The preadsorption control was performed on the polyclonal
pSer129 antibody because preadsorption controls on monoclonal antibodies always lead to loss
of labeling regardless of which proteins they bind in tissue (Saper, 2005). Preincubation of
polyclonal pSer129 antibodies with pSer129 blocking peptide led to dramatic loss of
immunoreactivity relative to adjacent sections from the same animal that were exposed to
unbound primary antibodies (Figure 21). These findings support the specificity of the primary
antibody.
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Fig. 21. Preadsorption of pSer129 antibodies with blocking peptide led to loss of immunoreactivity.
Two month-old mice were unilaterally infused with 1 h waterbath-sonicated alpha-synuclein fibrils (5 μg)
or an equal volume of phosphate-buffered saline (PBS) into the CA2/3 of hippocampus. Three months
later, sagittal brain sections were collected. Polyclonal antibodies against pSer129 were preadsorbed with
pSer129 blocking peptide or incubated alone for 24 h prior to application to tissue. Hoechst-labeled nuclei
are shown in blue. Shown are adjacent sections from the same fibril-infused animal, captured with
equivalent exposures and intensity scaling.

The second control for antibody specificity was to use two independent antibodies against the
same phosphorylation site, but with slightly different epitope sizes (for the sequence of the
immunogens, please see antibody Table 3). These polyclonal and monoclonal pSer129
antibodies led to the same patterns of staining, as expected (Figure 22). The staining overlap was
nearly complete, similar to what we reported previously (Mason et al., 2016). However, the
colocalization was not 100%, likely due to heterogeneity of the antibody clones, competition
between the two types of IgG clones, or exposure of slightly distinct epitopes within aggregated
and misfolded protein clumps.
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pSer129

pSer129
Fig. 22. Overlap of polyclonal and monoclonal pSer129 staining patterns. Mice were infused in CA2/3
with PBS or 5 μg alpha-synuclein fibrils. Sagittal brain sections were collected three months later. Shown
are dense inclusions in the hippocampus, labeled with polyclonal pSer129 antibodies (green) and
monoclonal pSer129 antibodies (red). The NeuN neuronal nuclear immunostain (purple) and Hoechst
nuclear stain (blue) are also shown to delineate cytoarchitectonic boundaries and identify neuronal
elements. Polyclonal pSer129 antibodies and monoclonal pSer129 antibodies were applied
simultaneously in this experiment, followed by the appropriate secondary antibodies.
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The proteasomal degradation tag ubiquitin is present in some, but not all pSer129+ structures

Most, but not all Lewy bodies and Lewy neurites contain ubiquitin (Kuzuhara et al., 1988,
Spillantini et al., 1998b). Indeed, prior to general availability of alpha-synuclein antibodies,
investigators employed ubiquitin immunostaining to demark Lewy pathology. For example, the
neuritic pathology in CA2/CA3 in Lewy body disease is densely immunoreactive for ubiquitin
(Dickson et al., 1991, Dickson et al., 1994, Mattila et al., 1999). Therefore, we investigated
whether the pSer129+ inclusions formed in our model are also Lewy-like in nature. Mice were
sacrificed 3 months after fibril infusions

in the CA2/3. Sagittal sections were collected and

immunostained for K48-linked ubiquitin and pSer129. Cellular proteins conjugated to K48linked ubiquitin chains are specifically targeted for proteasomal degradation (Nathan et al.,
2013). Alpha-synuclein is thought to clog the proteasome and inhibit its proteolytic function,
leading to a buildup of misfolded and aggregated proteins that are tagged with ubiquitin (Cuervo
et al., 2004, Ebrahimi-Fakhari et al., 2011a). Some, but not all pSer129+ structures were
colocalized with the ubiquitin marker of protein aggregates, as expected based on Spillantini’s
classic work that ubiquitin antibodies label fewer Lewy bodies than alpha-synuclein antibodies
(Kuzuhara et al., 1988, Spillantini et al., 1998b). (Figure 23). These findings are also consistent
with the work of Osterberg et al. showing pSer129+ inclusions at progressive stages of maturity,
with only mature inclusions bearing hallmarks of Lewy pathology (Osterberg et al., 2015).
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Enthorhinal
Cortex
Hippocampus
Fig. 23. pSer129+ inclusions harbor the ubiquitin tag for proteasomal degradation. Mice were infused
in the CA2/3 with PBS or 5 μg alpha-synuclein fibrils. Brain sections were collected three months later.
Shown are somal and neuritic inclusions in the hippocampus and entorhinal cortex, respectively.
Inclusions were labeled with pSer129 (red) and ubiquitin (green) antibodies. The NeuN neuronal nuclear
immunostain (purple) and Hoechst nuclear stain (blue) were employed to show cytoarchitectonic
boundaries and identify neuronal structures. Some, but not all pSer129+ structures were ubiquitin+.

Thioflavin-S reactive amyloid structures are present at the infusion site in fibril-treated animals

Lewy bodies are known to harbor proteins with β-sheet structures that form a dense core of
amyloid (Gallea and Celej, 2014). Therefore, we stained PBS or fibril-infused animals with the
Thioflavin S amyloid stain. Our experiments demonstrated the presence of Thioflavin S+
structures at the infusion site that were completely absent in PBS control mice (Figure 24). Highmagnification images of the Thioflavin+ structures revealed a similar morphology as perinuclear
and neuritic pSer129+ inclusions. However, as in our previous study, extrahippocampal regions
did not develop these dense Thioflavin+ structures. This suggests that inclusions at afferent sites
have not formed mature amyloid structures by three months post-infusion.
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PBS

Alpha-synuclein fibrils

Fig. 24. Amyloid structures at the fibril infusion site. Mice were infused in CA2/3 with PBS or 5 μg
alpha-synuclein fibrils. Brain sections were collected three months later. Shown are Thioflavin S+
structures (green) at the infusion site that were absent in PBS control mice. The Hoechst nuclear stain
(blue) was employed to delineate cytoarchitectonic boundaries. High-magnification views of the
Thioflavin S+ structures revealed a similar morphology as the perinuclear and neuritic pSer129 +
inclusions. Photos were captured from fibril and PBS-treated animals at the same exposures and intensity
scaling.

Alpha-synucleinopathy spreads through neuroanatomical circuits following infusion of fibrils
into CA2/3

In order to investigate the pattern of transmission of alpha-synucleinopathy following infusion of
fibrils into CA2/3, we investigated the topographical distribution of inclusions across the entire
brain. All fibril-infused animals exhibited dense inclusions that were immunopositive for
pathologically phosphorylated alpha-synuclein. As mentioned above, major afferents of the
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hippocampal formation include the septum, diagonal band, and entorhinal cortex, whereas minor
projections arise in the supramammillary nucleus, locus coeruleus, raphe, and ventral tegmental
area (Segal, 1977, Swanson and Cowan, 1977, Swanson, 1982, Vertes, 1992, Conde et al., 1995,
Yoshida and Oka, 1995, Gasbarri et al., 1997, Risold and Swanson, 1997, Acsady et al., 1998,
Naber and Witter, 1998, McKenna and Vertes, 2001, O'Mara et al., 2001, Francisco E. OluchaBordonau, 2015, Natalie L.M. Cappaert, 2015, Paxinos, 2015). Perinuclear or somal inclusions
appeared in the pyramidal cell layer of Ammon’s horn and the granule cell layer of the dentate
gyrus after fibril treatment (Fig 25 A and B). In addition, neuritic inclusions were found in the
stratum radiatum of CA3 and in the polymorph layer of the dentate gyrus, likely labeling the
mossy fiber pathway, because granule cells of the dentate gyrus send unmyelinated axons along
the mossy fiber pathway to the CA3 subregion of the hippocampus (Acsady et al., 1998).
Neuritic and perinuclear pSer129+ pathology following CA2/CA3 injections also extended into
the subiculum and presubiculum. Alpha-synucleinopathy was transmitted along the dorsoventral
axis of the hippocampus, with some interindividual variability in the extent of spread, possibly
due to slight differences in the placement of the infusate in this highly laminar structure.

In fibril-infused animals, there was evidence of extra-hippocampal pathology in various
amygdalar subnuclei, including the posteromedial cortical amygdala, the amygdalohippocampal
area, and the basal amygdaloid nuclei. Dense pathology was observed in the amygdalopirifom
transition area. Some animals exhibited sparse pathology in the dorsal nucleus of the
endopiriform claustrum, the lateral septum, and the rostral extent of the nucleus accumbens. The
pathology in the accumbens was found in the processes and not cell bodies, suggestive of some,
albeit limited anterograde transmission, consistent with the known projections of the
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hippocampus to the accumbens (Floresco et al., 2001). Very little, if any pathology was evident
in the medial septum, although this is a major source of hippocampal afferents (Acsady et al.,
1998, Natalie L.M. Cappaert, 2015, Paxinos, 2015). These findings strongly suggest some degree
of selective vulnerability to alpha-synucleinopathy, as has been discussed extensively in the
human literature (Braak et al., 2003a). According to Braak’s hypothesis, unmyelinated axons
require higher levels of energy to maintain axonal function compared to myelinated axons. High
energy demands could result in oxidative stress at the level of the mitochondrion, which would
be expected to increase neuron vulnerability to alpha-synuclein aggregation in PD (Braak et al.,
2003a, Braak et al., 2003b).

Had widespread diffusion of fibrils through the extracellular space been solely responsible for
the emergence of Lewy-like pathology, we would have expected to see inclusions in all areas
close the lateral ventricle by the site of infusion, such as the caudoputamen and thalamus, but this
was not the case (Figure 25A, B, D-Q).

In order to better understand the neuroanatomy of projections terminating at the site of fibril
infusion, we infused tracers at the same CA2/CA3 stereotaxic coordinates. For example, we
injected animals with biotinylated dextran amines (BDA) and collected the brains 7d postinfusion for exposure to a streptavidin-linked fluorophore. The 10kDa dextran amines travel
preferentially in the anterograde directions, although they are not exclusively transported only in
one direction. Following 10 kDa dextran amine injections, there was dense retrograde labeling in
layer II of the entorhinal cortex, as would be expected from the dense projections of the perforant
pathway, which originates in layer II of the entorhinal cortex and terminates in the dentate gyrus
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and CA3, among other hippocampal subregions (Acsady et al., 1998, Baks-Te Bulte et al., 2005,
Natalie L.M. Cappaert, 2015, Paxinos, 2015). In addition to the retrograde labeling of somata,
there was also dense anterograde BDA labeling of fibers in the deeper layers of the entorhinal
cortex (Figure 25 C, see white arrow). The existence of somal pSer129+ inclusions in the
superficial layers of the entorhinal cortex and the relative scarcity of pSer129+ fiber labeling in
the deeper layers may suggest preferential retrograde transmission of alpha-synucleinopathy in
these brain regions. In addition, the entorhinal pathology was mainly located in the ventromedial
part of the entorhinal cortex in our model, which suggests retrograde labeling from the ventral
hippocampus based on previous anatomical work (Fyhn et al., 2004). Only sparse, if any,
pathology was detected in the dorsal entorhinal cortex in some animals. Tract-tracing studies
using biotinylated dextran amines have demonstrated that the dorsolateral entorhinal cortex
projects to the dorsal hippocampus whereas the ventromedial portion of the entorhinal cortex
projects to the ventral hippocampus (Fyhn et al., 2004). Considered together with the pattern of
pSer129+ inclusions in the present study, these findings suggest that the ventromedial entorhinal
cortex develops Lewy-like pathology due to anterograde projections to the ventral parts of the
hippocampus, which exhibited dense inclusions in virtually all fibril-infused animals. These
findings support Braak’s hypothesis that most of the Lewy pathology is transmitted retrogradely
in humans. However, the clinical studies by Braak cannot answer this question as definitively as
our rodent work, because the pathology is initiated in multiple locations in humans, whereas in
mice the pathology was initiated in the hippocampus (Braak et al., 2003a, Braak et al., 2003b).
Understanding the direction of the transmission of the pathology has clinical implications, as it
might shed light on the mechanisms underlying inclusion spread and identify targets for novel
therapies. In this context, retrograde and anterograde transport mechanisms along the axon
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involve distinct molecular motors, dynein and kinesin, respectively, which may confer selectivity
to the direction of travel of alpha-synuclein (Colin et al., 2008).
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Fig. 25. Alpha-synucleinopathy is transmitted through neuroanatomical circuits following infusion of
fibrils into CA2/3. Two month-old CD1 mice were unilaterally infused with alpha-synuclein fibrils (5 μg)
into CA2/3 of hippocampus. Three months later, sagittal brain sections were collected and immunostained
for pathologically phosphorylated alpha-synuclein (pSer129; red). Large, high-quality microscopic
photomontages of pSer129 and nuclear labeling were stitched together and viewed with Adobe Illustrator
software on a tablet. (A and B) Sagittal schematics of only obvious and clearly visible brain
cytoarchitectonics (solid lines), myelinated fiber bundles (gray shading), pSer129+ neurites (red
flourishes), and pSer129+ somal inclusions (red dots) were then traced with the pencil and paintbrush
tools. All abbreviations are listed in Table 5. (C) Dense retrograde labeling in layer II, as would be
expected from the dense projections of the perforant pathway, and anterograde labeling in the deep layers
of the entorhinal cortex following injections of 10 kDa biotinylated dextran amines (BDA) in CA2/3.
BDA labeling is shown in green and Hoechst nuclear staining in blue. (D-Q) Examples of stitched
photomontages of pSer129 immunostaining and DRAQ5 nuclear labeling following fibril infusions in
CA2/CA3. These montages were used to generate the schematics shown in panels A and B.

Commissural spread of alpha-synucleinopathy

Early Parkinson’s disease is characterized by unilateral onset of clinical symptoms. However, the
reasons underlying the asymmetric nature of the disorder are poorly understood (Djaldetti et al.,
2006). One hypothesis is that there is unilateral exposure to a disease-precipitating insult, and
that the pathology is then transmitted along commissural fibers to the contralateral side only after
a delay. However, it is not yet known if Lewy pathology can travel through commissural
networks. In this study, we sought to investigate the commissural spread of alphasynucleinopathy through neuroanatomical circuits following unilateral infusions of alphasynuclein fibrils into CA2/3. As mentioned above, hippocampal commissural projections arise
largely from excitatory mossy cells in the hilar region of the dentate and from CA3 pyramidal
cells (Swanson et al., 1980, Zappone and Sloviter, 2001). FluoroGold tract-tracing studies reveal
that retrograde tracer injections in the medial hippocampus (that encompass the dentate gyrus)
elicit contralateral FluoroGold labeling that is exclusively in dentate hilar neurons, whereas
larger injections (that also involve CA3 and CA1) lead to contralateral labeling in CA3 as well as
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the hilum (Zappone and Sloviter, 2001). In the present study, mice were unilaterally infused with
alpha-synuclein fibrils or PBS into CA2/3 of hippocampus and sacrificed after three months.
Immunostaining for pathologically phosphorylated alpha-synuclein in coronal brain sections
revealed the formation of somal inclusions in contralateral CA3 pyramidal cells as well as
neuritic inclusions in the stratum oriens, lucidum, radiatum, and lacunosum moleculare (Figure
26). However, dentate hilar neurons only developed sparse, if any pathology, which again
suggests some degree of selective vulnerability to alpha-synucleinopathy. pSer129+ structures
were completely absent in PBS control mice. This spread of pathology through commissural
projections in our model suggests that similar neuroanatomical spread may explain the presence
of Lewy pathology in CA3 in patients. Had non-specific and widespread diffusion of fibrils
through the extracellular space been responsible for the emergence of Lewy-like pathology in the
contralateral hippocampus, we would have expected to see labeling in other contralateral
hippocampal subfields in addition to CA3.
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Fig. 26. Commissural spread of alpha-synucleinopathy through neuroanatomical circuits following
infusion of fibrils into CA2/3. Two month-old CD1 mice were unilaterally infused with alpha-synuclein
fibrils (5 μg) or PBS into CA2/3 of hippocampus. Three months later, coronal brain sections were
collected and immunostained for pathologically phosphorylated alpha-synuclein (pSer129; red). The
Hoechst neuronal stain (blue) was used to show cytoarchitectonic boundaries. (A) Shown are images of
pSer129 and Hoechst staining in the contralateral hippocampus in PBS and fibril-infused animals. Mice
infused with fibrils exhibited alpha-synucleinopathy in CA3 of the contralateral hippocampus. pSer129+
structures were absent in PBS control mice. All groups were stained in parallel and captured at the same
exposure and intensity scaling. (B) High-quality microscopic photomontages of pSer129 and nuclear
labeling were stitched together and viewed with Adobe Illustrator software on a tablet. Coronal
schematics of only obvious and clearly visible brain cytoarchitectonics (solid lines), myelinated fiber
bundles (gray shading), pSer129+ neurites (red flourishes), and pSer129+ somal inclusions (red dots) were
then traced with the pencil and paintbrush tools. Immunostaining for pathologically phosphorylated
alpha-synuclein revealed formation of somal inclusions in contralateral CA3 pyramidal cells as well as
neuritic inclusions in the stratum oriens, lucidum, radiatum and lacunosum moleculare. Dentate hilar
neurons only develop sparse, if any pathology, suggesting some degree of selective vulnerability. All
abbreviations are listed in Table 5.
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pSer129+ inclusions were formed in structures known to harbor anatomical connections with the
hippocampus and were dramatically higher in bilateral fibril-injected mice compared to PBStreated animals

Previous studies either did not report any memory deficits following unilateral hippocampal
injection of fibrils or never measured cognitive function (Luk et al., 2012a, Sacino et al., 2013).
Thus, we sought to develop a model of bilateral hippocampal alpha-synucleinopathy to increase
the potential for behavioral impairments and to avoid any possible compensatory effects in the
unlesioned hemisphere. Similar to unilateral injections, mice that were bilaterally infused with
fibrils into CA2/3 exhibited dense alpha-synucleinopathy in the hippocampal formation and
subiculum. Extrahippocampal pSer129+ inclusions were also located in the superficial layers of
the entorhinal cortex, the lateral septum, the nucleus accumbens, and in many amygdaloid
subnuclei, as with unilateral injections (see above). No inclusions were formed in the medial
septum. Thus, pSer129+ inclusions were again formed in some, but not all structures known to
harbor anatomical connections with the hippocampus (Segal, 1977, Swanson and Cowan, 1977,
Swanson, 1982, Vertes, 1992, Conde et al., 1995, Yoshida and Oka, 1995, Gasbarri et al., 1997,
Risold and Swanson, 1997, Acsady et al., 1998, Naber and Witter, 1998, McKenna and Vertes,
2001, O'Mara et al., 2001, Francisco E. Olucha-Bordonau, 2015, Natalie L.M. Cappaert, 2015,
Paxinos, 2015). Bilateral PBS infusions did not result in any alpha-synucleinopathy (Fig 27A).
Next, a blinded analysis revealed that the number of pSer129+ inclusions in CA1, CA2, CA3,
dentate gyrus, subiculum, and the amygdala (posteromedial cortical amygdala) of fibril-treated
mice were dramatically higher than PBS-infused mice (Figure 27B). However, there was great
variability in the number of inclusions, which we leveraged with a statistical correlation analysis,
as described further below.
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Fig. 27. pSer129+ inclusion counts are dramatically higher in bilateral fibril-injected mice compared to
PBS-treated animals. (A) Two month-old CD1 mice were bilaterally infused with alpha-synuclein fibrils
(5 μg) or PBS into CA2/3 of hippocampus. Three months later, sagittal brain sections were collected and
immunostained for pathologically phosphorylated alpha-synuclein (pSer129; green). The DRAQ5
neuronal stain (purple) was used to show cytoarchitectonic boundaries. Mice infused with fibrils into
CA2/3 of both hemispheres exhibited dense alpha-synucleinopathy in the hippocampal formation and
subiculum. Extrahippocampal pSer129+ inclusions were also located in the superficial layers of the
entorhinal cortex, the lateral septum, the nucleus accumbens, and in many amygdaloid subnuclei.
pSer129+ structures were absent in PBS control mice. (B) pSer129+ inclusion numbers were counted
manually by a blinded observer. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 vs PBS, Mann-Whitney U, (n = 8-10
mice/group). GrDG: granule cell layer of the dentate gyrus; MoDG: molecular layer of the dentate gyrus;
PMCo: posteromedial cortical amygdala; PrS: presubiculum. All other abbreviations are listed in Table 5.

Alpha synuclein fibril infusions had no effect on Hoechst+ and NeuN+ cell numbers
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Two studies suggest that there is no neuron loss in CA1, CA2/CA3, the dentate gyrus, or the
subiculum in Parkinson’s disease (Ince et al., 1991, Joelving et al., 2006). However, there is
selective neuron loss in lower presubiculum pyramidal neurons of the hippocampal formation in
dementia with Lewy bodies (Harding et al., 2002). Moreover, the amygdala is significantly
atrophied in Parkinson’s disease and in dementia with Lewy bodies (Cordato et al., 2000).
Therefore, we sought to quantify all cells (i.e. Hoechst+) and specifically neurons (i.e. NeuN+) in
the regions with the densest alpha-synucleinopathy, in order to investigate the similarities of this
model with the human condition. Mice were bilaterally infused with alpha-synuclein fibrils (5
μg) or PBS into CA2/3 of hippocampus. Three months later, sagittal brain sections were
collected and stained for neuronal nuclear marker NeuN and the nuclear marker Hoechst. NeuN+
and Hoechst+ cells were counted by a blinded observer. Alpha-synuclein infusions had no effect
on cell numbers in this model, including in the presubiculum (Figure 28). Thus, this model does
not recapitulate all the features of Lewy body dementia. However, the general lack of cell loss in
the hippocampal formation is similar to the absence of cell death in the hippocampal formation
in Parkinson’s disease.
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Fig. 28. Alpha-synuclein infusions had no effect on Hoechst+ and NeuN+ cell numbers. Two monthold CD1 mice were bilaterally infused with alpha-synuclein fibrils (5 μg) or PBS into CA2/3 of
hippocampus. Three months later, sagittal brain sections were collected and labeled with NeuN antibodies
and Hoechst. NeuN+ and Hoechst+ cells were counted manually by a blinded observer. Alpha-synuclein
infusions had no effect on the number of Hoechst+ and NeuN+ cells in any of the examined structures. (n
= 8-10 mice/group). GrDG: granule cell layer of the dentate gyrus; MoDG: molecular layer of the dentate
gyrus; PMCo: posteromedial cortical amygdala; PrS: presubiculum.
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Alpha-synucleinopathy is correlated with behavioral deficits

Approximately 80% of Parkinson’s disease patients develop dementia (Aarsland et al., 2003).
Alpha-synucleinopathy in the anterior cingulate gyrus, superior frontal gyrus, temporal and
entorhinal cortices, the amygdaloid complex, and hippocampal CA2 are significantly associated
with dementia in Parkinson’s disease (Ince et al., 1991). Disruptions in memory are also
associated with tissue atrophy in CA1, CA3, and the subiculum in Parkinson’s disease (Beyer et
al., 2013). The amygdala is known to be significantly atrophied in Parkinson’s disease and in
dementia with Lewy bodies (Cordato et al., 2000). Although one study failed to observe any
correlation between CA2 Lewy pathology and the severity or duration of dementia (Harding and
Halliday, 2001), others have reported that Lewy neurite density in CA2 is correlated with
cognitive deficits (Cordato et al., 2000, Kalaitzakis et al., 2009). As mentioned above, there is no
neuron loss in CA1, CA2/CA3, the dentate gyrus, or subiculum in Parkinson’s disease (Ince et
al., 1991, Joelving et al., 2006). However, there is selective neuron loss in lower presubiculum
pyramidal neurons of the hippocampal formation in dementia with Lewy bodies (Harding et al.,
2002). We presented data above showing no overt cell loss in any subregion of the hippocampal
formation. However, we have also shown robust Lewy-like pathology in the hippocampal
formation, which may be linked to the development of cognitive deficits. Thus, we performed
the novel object and novel place recognition tests on bilaterally-infused animals.

Olfactory dysfunction is common non-motor symptom in patients with Parkinson disease and has
been associated with deposition of Lewy-like inclusions in olfactory structures (Bohnen et al.,
2008). Smell impairments in Parkinson’s disease are also correlated with loss of dopaminergic
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innervation of the hippocampus, amygdala, and dorsal and ventral striatum (Bohnen et al., 2008).
Clinical reports suggest that hyposmia in Parkinson’s disease is associated with hippocampal
pathology (Bohnen et al., 2008). This may reflect the dense neuroanatomical projections of CA1
to olfactory structures (Swanson and Cowan, 1977, van Groen and Wyss, 1990, Brunjes et al.,
2005). Moreover, following an emotional event, the amygdala and hippocampus act
synergistically in the process of long-term memory consolidation (Richter-Levin and Akirav,
2000, Richter-Levin, 2004). Therefore, Lewy pathology in the hippocampal formation and
amygdala may lay the foundation for both the memory and olfactory deficits in patients with
Parkinson’s disease. The CA1 and CA3 subregions are both implicated in spatial learning and
there is evidence that dorsal CA1 is involved in the processing of object recognition (Sauvage et
al., 2013). In addition, aging and alpha-synucleinopathy both lead to impaired synaptic plasticity
in the dentate gyrus (Gureviciene et al., 2009). Thus, we infused preformed alpha-synuclein
fibrils into hippocampal CA2/CA3 in both hemispheres and performed the novel object and
novel place recognition tests for learning and memory and buried peanut test for olfactory
function two and three months later. Animals with bilateral infusions of alpha-synuclein fibrils
did not exhibit significant functional deficits at two or three months post-infusion compared to
PBS-infused animals (Fig. 29).

The measurements of Lewy-like inclusion counts in hippocampal subregions and the amygdala
suggested a high degree of variability in inclusion counts across animals, likely due to 1) slight
differences in the placement of the infusate in a palisade-like structure such as the hippocampus
or 2) inter-animal variability in vulnerability. Thus, we investigated if there is a correlation
between Lewy-like inclusion counts and behavioral deficits. We discovered a significant
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correlation between pSer129+ inclusions counts in the dentate gyrus, the region with the densest
pathology in following CA2/3 injection of fibrils, and behavioral deficits in mice treated with
alpha-synuclein fibrils (Fig. 30). In the present study, the dentate gyrus developed the densest
Lewy-pathology, likely via the axons of the mossy fibers that arise in the dentate fascia and
terminate at the site of injection, CA2/3 (Acsady et al., 1998, Paxinos, 2015). In Parkinson’s
disease, CA2 develops greater inclusion numbers than the dentate gyrus (Parkkinen et al., 2008).
However, the pathology in CA2 is not the densest in our model. One potential explanation for
this observation is that labeling in CA2 would involve anterograde uptake into the somata, which
may be less likely than uptake at the level of the synapse, as suggested by our previous work
(Mason et al., 2016). In other words, there may be greater uptake of fibrils by axon terminals of
mossy fibers projecting from the dentate gyrus to the site of infusion, compared to direct
anterograde update of fibrils by CA2 perikarya.

In this study, we also discovered that the Lewy-like pathology in molecular layer of dentate
gyrus is positively correlated with the latency to find a buried peanut test, suggesting olfactory
dysfunction at 2 months (Fig. 30). Similarly, alpha-synucleinopathy in the granule cell layer and
molecular layer of the dentate gyrus was negatively correlated with novel object recognition at 2
months and spatial memory at 3 months, respectively (Fig. 30). In short, our data suggests that
alpha-synucleinopathy in the dentate gyrus is statistically correlated with behavioral deficits in
the absence of frank neurodegeneration at these sites. Some of the effects may be evident only at
2 months and not at 3 months because the animals have grown accustomed to the testing
paradigm (i.e. testing fatigue) or some of the pathology is cleared up with the passage of time
post-infusion. This hypothesis could be readily tested with a temporal kinetic analysis of Lewy-
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like pathology over the course of 1, 2, 3, and 6 months post-infusion in future studies.
Furthermore, by infusing human alpha-synuclein into the mouse brain, we could determine if the
fibrils are cleared over time by using a human-specific alpha-synuclein antibody. Despite these
limitations, our study is the first to exhibit significant correlation between pSer129+ inclusions in
the dentate gyrus and functional deficits following bilateral infusion of fibrils. However, these
observations are correlative, as we do not have evidence that the Lewy pathology is actually
causing functional deficits. If the fibrils were eliciting functional deficits, we would have
expected significant effects in Figure 29. It remains possible that inter-animal differences in
vulnerability to Lewy pathology (rather than differences in Lewy pathology per se) may underlie
differences in behavioral performances in the memory and olfactory tests. For example, one
might speculate that animals that are genetically predisposed to be more physically fit may be
less vulnerable to Lewy-like pathology and may also be superior performers on cognitive and
olfactory tasks. For example, studies in mice have shown both intra- and inter-strain differences
in running speed (Billat et al., 2005). This could explain the correlation between Lewy-like
pathology and the behavioral tests in the absence of significant effects of the fibrils in Figure 29.
This discussion reflects the important differences between associations that are merely
correlative and those that are established as causal links. If our results can be translated to
humans, the data we have collected suggest that other pathologies besides the presence of Lewy
structures per se may underlie dementia in the human condition. Alternatively, the presence of
Lewy structures in the neocortex may exert a greater influence on cognitive symptoms than
Lewy pathology in the allocortical hippocampus. Yet another possibility is that degeneration of
presubicular neurons is a prerequisite for the emergence of dementia symptoms, a feature of
dementia with Lewy bodies
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that we failed to recapitulate (Harding et al., 2002). Neurodegeneration may have become
evident in our model had our animals lived longer, as suggested by some previous fibril studies
(Luk et al., 2012a, Paumier et al., 2015).
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Fig. 29. Animals with bilateral infusions of alpha-synuclein fibrils did not exhibit any
functional deficits at two or three months post-infusion. Two month-old CD1 mice were bilaterally
infused with alpha-synuclein fibrils (5 μg) into CA2/3 of hippocampus. (A-B) Olfactory function was
assessed using the buried peanut test at 2 and 3 months post-infusion. (C-F) Memory function was also
measured using novel object/place recognition tests at the same timepoints. Bilateral infusions of alphasynuclein fibrils did not elicit any functional deficits at two or three months post-infusion compared to the
PBS group (n = 8-10 mice/group).
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Discussion

In our previous study, we used FluoroGold tract-tracing combined with fibril infusions to show
that alpha-synucleinopathy is transmitted in the retrograde direction from olfactory structures
into areas that send first-order projections into the OB/AON (Mason et al., 2016). In the present
study, alpha-synuclein fibrils were infused into CA2/3 of the hippocampus in the quest for a
model of dementia with Lewy bodies or Parkinson’s disease dementia. We examined the brains
for Lewy-like pathology three months after unilateral fibril infusions. Perinuclear inclusions
appeared in the pyramidal cell layer of Ammon’s horn as well the granule cell layer of the
dentate gyrus following CA2/CA3 injections. Neuritic and perinuclear inclusions extended into
the subiculum and presubiculum. Extra-hippocampal pathology was evident in the superficial
layers of the entorhinal cortex, the lateral septum, the nucleus accumbens, and in many
amygdaloid subnuclei. As discussed earlier, all of these regions have been shown to project into
the hippocampal formation (Segal, 1977, Swanson and Cowan, 1977, Swanson, 1982, Vertes,
1992, Conde et al., 1995, Yoshida and Oka, 1995, Gasbarri et al., 1997, Risold and Swanson,
1997, Acsady et al., 1998, Naber and Witter, 1998, McKenna and Vertes, 2001, O'Mara et al.,
2001, Paxinos, 2015), supporting our previous work that the areas developing Lewy pathology
share neuroanatomical connections with the site of infusion and are not merely distributed close
to the infusion site (Mason et al., 2016). However, not all afferents exhibited Lewy pathology,
such as the medial septum and diagonal band of Broca, which send dense projections into the
hippocampus (Yoshida and Oka, 1995, Paxinos, 2015). These findings suggest that some
neurons are less vulnerable to alpha-synucleinopathy, a conclusion that is entirely consistent with
the clinical work on Lewy body disorders (Braak et al., 2003a).
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The development of dense perinuclear and neuritic inclusions following fibril infusions was
confirmed with two independent (monoclonal and polyclonal) pSer129 antibodies and
preadsorption control experiments confirmed a loss of pSer129 staining. The Thioflavin stain
labeled cells at the infusion site and some, but not all inclusions contained ubiquitin. Threedimensional confocal analyses revealed that most perinuclear pSer129+ inclusions were formed
within cells expressing the neuronal nuclear marker NeuN, although this subject has been a
matter of some controversy (Sacino et al., 2013). It would be surprising if Lewy-like pathology
were not in neuronal cells, as alpha-synuclein is a neuronal protein. We collected evidence of
commissural spread of alpha-synucleinopathy through neuroanatomical circuits, as we only
observed contralateral hippocampal labeling in hippocampal subregions known to project to the
opposite hemisphere. Our study is the first to reveal that there is a robust correlation between
pSer129+ inclusions in the dentate gyrus and cognitive and olfactory deficits following bilateral
infusion of fibrils. The behavioral deficits were not correlated with cell numbers (not shown) as
there was no overt neurodegeneration, but could have arisen due to inter-individual differences in
synaptic function and protein quality control systems. Animals with greater autophagic and
proteasomal clearance may have superior synaptic function and also clear misfolded proteins
better. Alternatively, one possibility is that the Lewy-like inclusions observed in the present
study were not mature enough at three months and had not seeded sufficient pathology to elicit
substantial behavioral deficits. Future studies with longer survival timepoints are warranted, as
Luk, Paumier and colleagues have shown that fibril infusions in the striatum only lead to robust
degeneration at 6 months post-infusion (Luk et al., 2012a, Paumier et al., 2015).

Labeling with the pSer129 antibody is known to be subject to cross-reaction with neurofilament-
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L (Sacino et al., 2014b). Therefore, we have used several controls to confirm our pSer129+
staining. Two independent (monoclonal and polyclonal) pSer129 antibodies revealed the same
labeling patterns (Figure 22) and preadsorption control experiments confirmed a loss of pSer129
staining (Figure 21). Although we cannot rule out all cross-reactivity with certitude (Sacino et
al., 2014a), the high-intensity labeling of inclusions is quite distinct from background, as evident
from the stitched montages (Figures 19 and 27) and the blinded quantification shows that PBS
animals do not exhibit pSer129+ structures (Figure 27).

One limitation of the present study is that we cannot completely rule out potential diffusion and
non-specific uptake of fibrils throughout the interstitial space of the brain following fibril
injections in CA2/3. However, the caudoputamen and thalamus are almost free from pSer129
label despite being close to the ventricles and to the epicenter of the infusion. In this context, it is
worth mentioning the alpha-synuclein protein is found at high levels in the cerebrospinal fluid,
where it may serve as a biomarker for the diagnosis of Parkinson’s disease (Gao et al., 2015).
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Conclusions

In the present study, multiple models of Parkinson’s disease that mimic oxidative or proteotoxic
stress were developed in order to test the efficacy of neuroprotective molecules. This was
accomplished because no one model can mimic the range of pathologies of a complex disorder
such as Parkinson’s disease. Importantly, if a neuroprotectant can ameliorate multiple types of
injury, it is far more likely to succeed in the clinic. The models established here include the
following: 1) proteasome inhibitor infusions into the mouse hippocampus to inhibit the
degradation of misfolded proteins and elicit cell death within 7 days, 2) 6-OHDA infusions into
the mouse striatum to elicit oxidative stress and kill dopaminergic neurons within 7-10 days, and
3) alpha-synuclein fibril infusions into the mouse and rat hippocampus and/or striatum to seed
the misfolding of endogenous alpha-synuclein and elicit the formation of Lewy bodies and Lewy
neurites. We have reproduced the robustness and reliability of the 6-OHDA model of
Parkinson’s disease, and verified true dopaminergic neurodegeneration, as opposed to mere loss
of dopaminergic phenotype. We validated the use of retrograde tracer FluoroGold as a more
sensitive tool than measurements of either TH cell numbers or TH levels. We also gathered data
suggesting that FluoroGold exerts some mild toxicity, as evident in nigral area measurements,
but that it did not significantly affect the toxicity of 6-OHDA in either the striatum or the nigra.
We validated the use of the 16-bit, high sensitivity Odyssey imager as an initial screening tool to
measure loss of the nigrostriatal pathway in an economical manner. Next, we tested two
therapies, the antioxidant N-acetyl-L-cysteine (NAC) and neurosteroid dehyroepiandrosterone
sulfate (DHEAS), in one of these animal models of Parkinson’s disease. We gathered support for
the hypothesis that NAC protects dopaminergic terminals against 6-OHDA at short timeframes,
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as shown by Munoz and colleagues (Munoz et al., 2004). However, we extended previous work
by showing that the protective effects of NAC in our 6-OHDA model wane by three weeks postinfusion. These results demonstrate the importance of sacrificing animals at multiple timepoints
when assessing the efficacy of neuroprotectants, particularly when modeling long-term
conditions such as neurodegenerative disorders of the brain. Clinical trials of NAC have been
relatively successful, including in Parkinson’s disease patients, but have shown that NAC
improves dopamine transporter binding by only 10% (Monti et al., 2016). Our findings that NAC
can be slightly toxic offer one explanation for the small size of the effects in the Monti et al.
study, and should serve as a warning to clinical investigators who intend to deliver NAC at
similar doses for long timeframes. Another explanation for the discrepancy between our results
and that of the study by Monti et al is that we used higher doses of NAC. However, our dose of
NAC was based on a large body of previous work, including many clinical studies (Munoz et al.,
2004, Chakraborti et al., 2008, Bachle et al., 2011, Smaga et al., 2012, Comparsi et al., 2014,
Gunay et al., 2014, Jaccob, 2015, Prakash et al., 2015, Soleimani Asl et al., 2015, Truini et al.,
2015).

In the present study, we observed that neither alpha-synuclein infusions nor DHEAS injections
led to significant effects on novel object or place recognition, due to technical limitations such as
improper sonication parameters and application of low doses of fibrils. During the same
timeframe, the Leak lab discovered that 1h waterbath sonication of the fibrils renders the alphasynuclein model much more aggressive and robust. Therefore, we infused PBS or synuclein
fibrils in CA2/CA3 of the hippocampus and sacrificed mice three months later. These mice
developed robust Lewy-like pathology in the hippocampus and at some, but not all the sites that
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send first-order efferent projections to the hippocampus, such as the amygdala, entorhinal cortex,
and lateral septum (Yoshida and Oka, 1995, Acsady et al., 1998, Pikkarainen et al., 1999, BaksTe Bulte et al., 2005, Paxinos, 2015). Notably, our results strongly support the selective
vulnerability to alpha-synucleinopathy that is evident in all human Lewy body disorders, as the
projection from the medial septum/diagonal band was spared in our material. In Parkinson’s
disease, the basal forebrain does develop Lewy pathology (Hall et al., 2013, Hall et al., 2014),
but our findings suggest that alpha-synuclein inclusions may not develop specifically in those
medial septal neurons that project directly into the hippocampal formation.

We conducted olfactory and memory tests 2 and 3 months before sacrifice and discovered
correlations between alpha-synuclein inclusion counts and olfactory and cognitive impairments.
However, these observations are strictly correlational and thus far we do not have strong
evidence that the Lewy pathology per se is the cause of poor cognitive function. Instead, we
speculate that inter-animal differences in the underlying vulnerability to alpha-synucleinopathy
due to varying levels of physical fitness/protein quality control may make some animals more
likely to succumb to the misfolding and phosphorylation of alpha-synuclein. Further studies with
longer survival timeframes are needed to address this limitation of the fibril model, as discussed
further below.

The dentate gyrus may have developed the highest inclusion numbers in the present study
because it sends the densest afferents—the massive mossy fiber pathway—to the site of infusion,
CA2/CA3 (Acsady et al., 1998, Paxinos, 2015). In Parkinson’s disease, CA2 develops greater
inclusion numbers than the dentate gyrus, but may not have developed the most robust Lewy
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pathology in the present study because of lack of anterograde uptake of fibrils into the somata.
The CA2/CA3 study also showed transmission of alpha-synucleinopathy into superficial layer II
of the entorhinal cortex, suggesting that the massive perforant pathway was seized by the Lewy
pathology. As in our previous work, we did not collect evidence of robust transmission of
pathology in the anterograde direction, although some transmission of Lewy-like pathology to
the accumbens was observed, which receives afferent projections from the hippocampus
(Floresco et al., 2001). Furthermore, the pathology in the accumbens was found in fibers and not
in somata, which is also consistent with anterograde transmission. In contrast, much of the
pathology in the entorhinal cortex was perinuclear, suggestive of retrograde labeling.

Future directions of the present work include studies in aged animals and animals sacrificed at
longer survival periods, to facilitate additional seeding of alpha-synuclein molecules, increase
the potential for presubicular degeneration and the emergence of robust behavioral deficits.
Additional time until sacrifice would also increase the potential for transynaptic transport of
alpha-synucleinopathy. Alternatively, the results of the present study might suggest that Lewy
pathology in CA2 in humans is not causally linked to cognitive deficits and that the deficits are
only correlated with CA2 alpha-synucleinopathy due to the parallel influence of a third variable
on the evolution of Lewy pathology and memory function.

In conclusion, we have developed animal models of the oxidative and proteinopathic stressors
that are evident in postmortem tissue from Parkinson’s patients. Each model has unique strengths
and limitations that may limit their predictive validity, similar to all other rodent disease models.
For this reason, we developed multiple models for the preclinical testing of new or established
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therapies. Future therapies that are efficacious in both the 6-OHDA and the fibril model may
have greater potential for eventual success in the clinic.
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Appendix

Table 3: Primary antibodies

Primary Antibody

Source

Company

Catalog #

Lot #

Dilution

Anti-tyrosine
hydroxylase

Sheep

Millipore

AB1542

2554850

1:1000

Anti-fluorescent gold

Rabbit

Millipore

AB153-1

2533847

1:3000

GFAP

Rabbit

DAKO

Z0334

20001046

1:1000

Mouse

Gift from
Kelvin Luk
(81A)
(Waxman and
Giasson, 2008)

-

-

Anti-α-synuclein
(pSer129)
(aa 124 – 134;
AYEMPSpEEGYQ)

Anti-α-synuclein
(pSer129)

1:5000

Rabbit

Abcam

Ab59264

GR52476-25

1:300

Anti K48-linked
ubiquitin

Rabbit

Millipore

05-1307

2299608

1:500

Anti-NeuN

Guinea pig

Millipore

ABN90

2031353

1:6000

(aa 127-131; MPSPEE)
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Table 4: Secondary antibodies

Secondary Antibody

Source

Company

Catalog #

Lot #

Dilution

Anti-sheep @800

Donkey

Jackson
Laboratories

713-655-147

106089

1:500

Anti-sheep @488

Donkey

Life Technologie

A11015

1567206

1:500

Anti-rabbit @ 700

Donkey

Jackson
Laboratories

711-625-152

111285

1:500

Anti-guinea pig @ 790

Donkey

Jackson
Laboratories

706-655-148

106036

1:1000

Anti-guinea pig@ 647

Donkey

Jackson
ImmunoResearch

706-605-148

123960

1:700

Anti-guinea pig @ 488

Donkey

Jackson
ImmunoResearch

706-545-148

108077

1:1000

Anti-mouse @680

Donkey

Jackson
ImmunoResearch

715-625-151

106244

1:1000

Anti-mouse @ 555

Goat

Invitrogen

A21424

1141876

1:1000

Anti-mouse @ 488

Donkey

Life Technologies

A21202

1423052

1:800

Donkey

Jackson
ImmunoResearch

711-605-152

123104

Donkey

Jackson
ImmunoResearch

711-545-152

120705

1:700

Anti-rabbit@ 546

Goat

Life Technologies

A11035

1579044

1:500

Anti-rabbit @ 555

Goat

Life Technologies

A21429

1562309

1:800

Anti-rabbit @ 647

Anti-rabbit @ 488
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Table 5: Abbreviations

5N
7n
7N
8n
A30
AA
ac
aca
Acb
aci
acp
AHi
AMG
AOB
AOD
AOE
AOM
AON
AOP
AOV
APir
AV
bic
BLA
BMA
CA1
CA2
CA3
cc
CeA
CEnt
cp
CPu
cst
CxA
DCIC
DEn
DG
DLEnt
DS
DTT

motor trigeminal nucleus
facial nerve
facial nucleus
vestibulocochlear nerve
cingulate cortex area 30
anterior amygdaloid area
anterior commissure
anterior commissure, anterior part
nucleus accumbens
anterior commissure, intrabulbar
anterior commissure, posterior part
amygdalohippocampal area
amygdala
accessory olfactory bulb
anterior olfactory area, dorsal
anterior olfactory nucleus, external
anterior olfactory nucleus, medial
anterior olfactory nucleus
anterior olfactory area, posterior
anterior olfactory area, ventral
amygdalopiriform transition area
anteroventral thalamic nucleus
brachium of the inferior colliculus
basolateral nucleus of amygdala
basomedial nucleus of amygdala
cornu ammonis, field 1
cornu ammonis, field 2
cornu ammonis, field 3
corpus callosum
central nucleus of amygdala
caudomedial entorhinal cortex
cerebral peduncle
caudoputamen
commissural stria terminalis
cortex-amygdala transition zone
pericentral nucleus of inferior colliculus
dorsal nucleus of the endopiriform
claustrum
dentate gyrus
dorsolateral entorhinal cortex
dorsal subiculum
dorsal tenia tecta
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HDB
HP
ic
IC
lab
LH
lo
LOT
Lrt
LS
LSd
LSI
LSv
LTDg
LV
M2
MD
MEA
MEnt
mlf
MoDG
MS
mt
OB
och
opt
PaS
Pir
PMCo
Pn
Pr5
PrG
PRh
PrS
rf
rms
Rtg
S
S1
S1BF
SC
Scc

horizontal limb of the diagonal band
hippocampus
internal capsule
inferior colliculus
longitudinal association bundle
lateral habenula
lateral olfactory tract
nucleus of the lateral olfactory tract
lateral reticular nucleus
lateral septal nucleus
lateral septal nucleus, dorsal part
lateral septal nucleus
lateral septal nucleus, ventral part
laterodorsal tegmental nucleus
lateral ventricle
secondary motor cortex
mediodorsal thalamic nucleus
medial amygdala
medial entorhinal cortex
medial longitudinal fasciculus
molecular layer of the dentate gyrus
medial septal nucleus
mammillothalamic tract
olfactory bulb
optic chiasm
optic tract
parasubiculum
piriform cortex
posteromedial cortical amygdala
pontine nuclei
principal trigeminal nucleus
pregeniculate nu
perirhinal cortex
presubiculum
rhinal fissure
rostral migratory stream
rostral temporal gyrus
subiculum
primary somatosensory cortex
somatosensory 1, barrel field
superior colliculus
splenium of corpus callosum

ec
ECIC
Ect
Ent
EPl
f
FC
fi
fmi
fmj
fr
gcc
Gl
GP
GrDG
GrO

external capsule
external nucleus of inferior colliculus
ectorhinal cortex
entorhinal cortex
external plexiform layer, olfactory bulb
fornix
frontal cortex
fimbria
forceps minor of the corpus callosum
forceps major of the corpus callosum
fasciculus retroflexus
genu of corpus callosum
glomerular layer, olfactory bulb
globus pallidus
granular layer of dentate gyrus
granule cell layer of olfactory bulb
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sm
SNpr
sp5
Sp
st
SuG
SVZ
TeA
Tu
VDB
VM
VMH
VTT
VS

stria medullaris
substantia nigra pars reticulata
spinal trigeminal tract
spinal trigeminal nucleus
stria terminalis
superficial gray layer of the superior
colliculus
subventricular zone
temporal cortex, association area
olfactory tubercle
ventral diagonal band
ventromedial thalamic nucleus
ventromedial hypothalamic nucleus
ventral tenia tecta
ventral subiculum

